Iridium

Overzicht wetenschappelijke publicaties vermeld in PubMed

1. Kaidar-Person O, Meattini I, Zippel D, Poortmans P. Apples and oranges: comparing partial breast irradiation techniques. Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):780-782. doi: 10.1016/j.rpor.2020.07.008. Epub 2020 Aug 14. PMID: 32904220; PMCID: PMC7451739.
 
2. Dirix P, Wyld L, Paluch-Shimon S, Poortmans P. Time for More Inclusive Cancer Trials. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1431-1434. doi: 10.6004/jnccn.2020.7652. PMID: 33022651.
 
3. F Nascimento L, Verellen D, Goossens J, Struelens L, Vanhavere F, Leblans P, Akselrod M. Two-dimensional real-time quality assurance dosimetry system using μ-Al2O3:C,Mg radioluminescence films. Phys Imaging Radiat Oncol. 2020 Oct 5;16:26-32. doi: 10.1016/j.phro.2020.09.008. PMID: 33458340; PMCID: PMC7807545.
 
4. Fastner G, Leonardi MC, Poortmans PM. Targeted Intraoperative Radiotherapy for Early Breast Cancer. JAMA Oncol. 2020 Oct 1;6(10):1636-1637. doi: 10.1001/jamaoncol.2020.2719. Erratum in: JAMA Oncol. 2020 Oct 1;6(10):1641. PMID: 32789481.
 
5. Ratosa I, Chirilă ME, Steinacher M, Kozma E, Vojtíšek R, Franco P, Poortmans P. Hypofractionated radiation therapy for breast cancer: Preferences amongst radiation oncologists in Europe - Results from an international survey. Radiother Oncol. 2020 Oct 13;155:17-26. doi: 10.1016/j.radonc.2020.10.008. Epub ahead of print. PMID: 33065187.
 
6. Brouwer CL, Dinkla AM, Vandewinckele L, Crijns W, Claessens M, Verellen D, van Elmpt W. Machine learning applications in radiation oncology: Current use and needs to support clinical implementation. Phys Imaging Radiat Oncol. 2020 Nov 30;16:144-148. doi: 10.1016/j.phro.2020.11.002. PMID: 33458358; PMCID: PMC7807598.
 
7. Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart M, Poortmans P, Zeidan YH. De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost? Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1040-1046. doi: 10.1016/j.ijrobp.2020.06.078. Epub 2020 Aug 28. PMID: 32861819.
 
8. Oeyen S, Liégeois V, De Laere B, Buys A, Strijbos M, Dirix P, Meijnders P, Vermeulen P, Van Laere S, Dirix L. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Nov 23. doi: 10.1038/s41391-020-00304-1. Epub ahead of print. PMID: 33230201.
 
9. Billiet C, Chiairi I, Berzenji L, Van Schil PE. Tumeurs de petits stades. La chirurgie a-t-elle encore sa place ? [Early-stage lung cancer: Is there still a role for surgery?]. Rev Mal Respir. 2020 Nov;37(9):735-742. French. doi: 10.1016/j.rmr.2020.06.018. Epub 2020 Oct 12. PMID: 33059960.
 
10. Roeder F, Calvo FA, Asencio JM, Ferrer Albiach C, Poortmans P. In response to Haas RL et al. Radiother Oncol. 2020 Oct 21:S0167-8140(20)30850-1. doi: 10.1016/j.radonc.2020.10.014. Epub ahead of print. PMID: 33098928.
 
11. Fiagan YAC, Bossuyt E, Nevens D, Dirix P, Theys F, Gevaert T, Verellen D. In vivo dosimetry for patients with prostate cancer to assess possible impact of bladder and rectum preparation. Tech Innov Patient Support Radiat Oncol. 2020 Nov 24;16:65-69. doi: 10.1016/j.tipsro.2020.10.005. PMID: 33294646; PMCID: PMC7701258.
 
12. Bossuyt E, Weytjens R, Nevens D, De Vos S, Verellen D. Evaluation of automated pre-treatment and transit in-vivo dosimetry in radiotherapy using empirically determined parameters. Phys Imaging Radiat Oncol. 2020 Nov 9;16:113-129. doi: 10.1016/j.phro.2020.09.011. PMID: 33458354; PMCID: PMC7807610.
 
13. Kaidar-Person O, Kühn T, Poortmans P. Residual disease after mastectomy - Authors' reply. Lancet Oncol. 2020 Nov;21(11):e501. doi: 10.1016/S1470-2045(20)30622-7. PMID: 33152293.
 
14. Willmann J, Poortmans P, Monti AF, Grant W, Clementel E, Corning C, Reynaert N, Hurkmans CW, Andratschke N. Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group. Radiother Oncol. 2020 Nov 17;155:226-231. doi: 10.1016/j.radonc.2020.11.009. Epub ahead of print. PMID: 33217496.
 
15. Bosma SCJ, Hoogstraat M, van Werkhoven E, de Maaker M, van der Leij F, Elkhuizen PHM, Fourquet A, Poortmans P, Boersma LJ, Bartelink H, van de Vijver MJ; Young Boost Trial research group. A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients. Radiother Oncol. 2020 Nov 24;156:127-135. doi: 10.1016/j.radonc.2020.11.025. Epub ahead of print. PMID: 33245949.
 
16. Vandewinckele L, Claessens M, Dinkla A, Brouwer C, Crijns W, Verellen D, van Elmpt W. Overview of artificial intelligence-based applications in radiotherapy: Recommendations for implementation and quality assurance. Radiother Oncol. 2020 Dec;153:55-66. doi: 10.1016/j.radonc.2020.09.008. Epub 2020 Sep 10. PMID: 32920005.
 
17. Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Engelen A, De Brouwer P, Struikmans H, Bartelink H; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1602-1610. doi: 10.1016/S1470-2045(20)30472-1. Epub 2020 Nov 2. Erratum in: Lancet Oncol. 2021 Jan;22(1):e5. PMID: 33152277.
 
18. Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, Dégi C, Delgado Bolton RC, Gaga M, Lövey J, Luciani A, Pereira P, Prosch H, Saar M, Shackcloth M, Tabak-Houwaard G, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer. Lung Cancer. 2020 Dec;150:221-239. doi: 10.1016/j.lungcan.2020.08.017. Epub 2020 Sep 4. PMID: 33227525.
 
19. Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. Eur Urol Focus. 2020 Dec 29:S2405-4569(20)30312-6. doi: 10.1016/j.euf.2020.12.010. Epub ahead of print. PMID: 33386290.
 
20. Zeidan YH, Poortmans P. Don't Miss the Devil in the Details. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1133. doi: 10.1016/j.ijrobp.2020.05.054. Epub 2020 Nov 18. PMID: 33220225.
 
21. Méndez Romero A, Schillemans W, van Os R, Koppe F, Haasbeek CJ, Hendriksen EM, Muller K, Ceha HM, Braam PM, Reerink O, Intven MPM, Joye I, Jansen EPM, Westerveld H, Koedijk MS, Heijmen BJM, Buijsen J. The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. Int J Radiat Oncol Biol Phys. 2020 Dec 29:S0360-3016(20)34567-3. doi: 10.1016/j.ijrobp.2020.11.045. Epub ahead of print. PMID: 33451857.
 
22. Heymann S, Dipasquale G, Nguyen NP, San M, Gorobets O, Leduc N, Verellen D, Storme G, Van Parijs H, De Ridder M, Vinh-Hung V. Two-Level Factorial Pre-TomoBreast Pilot Study of Tomotherapy and Conventional Radiotherapy in Breast Cancer: Post Hoc Utility of a Mean Absolute Dose Deviation Penalty Score. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947759. doi: 10.1177/1533033820947759. PMID: 32940569; PMCID: PMC7502852.
 
23. Mercier C, Claessens M, Buys MSc A, Gryshkevych S, Billiet C, Joye I, Van Laere S, Vermeulen P, Meijnders P, Löfman F, Poortmans P, Dirix L, Verellen D, Dirix P. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial. Int J Radiat Oncol Biol Phys. 2020 Dec 8:S0360-3016(20)34638-1. doi: 10.1016/j.ijrobp.2020.11.066. Epub ahead of print. PMID: 33307151.
 
24. Marta GN, Ramiah D, Kaidar-Person O, Kirby A, Coles C, Jagsi R, Hijal T, Sancho G, Zissiadis Y, Pignol JP, Ho AY, Cheng SH, Offersen BV, Meattini I, Poortmans P. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. Clin Oncol (R Coll Radiol). 2020 Dec 22:S0936-6555(20)30484-2. doi: 10.1016/j.clon.2020.12.008. Epub ahead of print. PMID: 33358283.
 
25. Dhont J, Verellen D, Mollaert I, Vanreusel V, Vandemeulebroucke J. RealDRR - Rendering of realistic digitally reconstructed radiographs using locally trained image-to-image translation. Radiother Oncol. 2020 Dec;153:213-219. doi: 10.1016/j.radonc.2020.10.004. Epub 2020 Oct 8. PMID: 33039426.
 
26. Marta GN, Coles C, Kaidar-Person O, Meattini I, Hijal T, Zissiadis Y, Pignol JP, Ramiah D, Ho AY, Cheng SH, Sancho G, Offersen BV, Poortmans P. The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: A critical review. Crit Rev Oncol Hematol. 2020 Dec;156:103090. doi: 10.1016/j.critrevonc.2020.103090. Epub 2020 Aug 26. PMID: 33091800; PMCID: PMC7448956.
 
27. Wakefield DV, Sanders T, Wilson E, Hubler A, DeWeese TL, Smith BD, Eichler TJ, Slotman BJ, Lievens Y, Poortmans P, Cremades V, Ricardi U, Perez DAM, Sarria GR, Flores C, Malhotra SH, Li B, Ehmann M, Sarria GJ, Schwartz DL. Initial Impact and Operational Response of Radiation Oncology Practices to the COVID-19 Pandemic in the United States, Europe, and Latin America. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1402-1403. doi: 10.1016/j.ijrobp.2020.09.028. Epub 2020 Nov 18. PMID: 33427664; PMCID: PMC7671920.
 
28. Szturz P, Nevens D, Vermorken JB. Oligometastatic Disease Management: Finding the Sweet Spot. Front Oncol. 2020 Dec 22;10:617793. doi: 10.3389/fonc.2020.617793. PMID: 33415080; PMCID: PMC7783387.
 
29. Le Compte M, Komen N, Joye I, Peeters M, Prenen H, Smits E, Deben C, de Maat M. Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. Crit Rev Oncol Hematol. 2021 Jan;157:103190. doi: 10.1016/j.critrevonc.2020.103190. Epub 2020 Nov 28. PMID: 33310278.
 
30. Pavlidis N, Madry R, Peeters M, Sandrucci S, Markowska J, Peccatori F, Costa A, Eriksen JG, Ricardi U, Poetter R, Schrijvers D, Vermorken JB; in addition to a list of contributors. ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016-2019). J Cancer Educ. 2021 Jan 2. doi: 10.1007/s13187-020-01947-3. Epub ahead of print. PMID: 33387267.
 
31. Ostheimer C, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano FA, Sautter L, López G, Fleischmann DF, Niyazi M, Käsmann L, Kaul D, Thieme AH, Billiet C, Dobiasch S, Arnold CR, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje CM, Baues C, Trommer M, Skripcak T, Medenwald D. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlenther Onkol. 2021 Jan 7. doi: 10.1007/s00066-020-01727-4. Epub ahead of print. Erratum in: Strahlenther Onkol. 2021 Mar 5;: PMID: 33410959.
 
32. Gasparri ML, Poortmans P, Banys-Paluchowski M, Bonci EA, Di Micco R, Condorelli R, Matrai Z, Dubsky P, Gentilini OD, Kuehn T. What we learned in axillary management of breast cancer patients at the American society of clinical oncology (ASCO) 2020 virtual meeting? The EUBREAST point of view. EClinicalMedicine. 2021 Jan 14;31:100708. doi: 10.1016/j.eclinm.2020.100708. PMID: 33490932; PMCID: PMC7811045.
 
33. Kaidar-Person O, Nissen HD, Yates ES, Andersen K, Boersma LJ, Boye K, Canter R, Costa E, Daniel S, Hol S, Jensen I, Lorenzen EL, Mjaaland I, Nielsen MEK, Poortmans P, Vikström J, Webb J, Offersen BV. Postmastectomy Radiation Therapy Planning After Immediate Implant-based Reconstruction Using the European Society for Radiotherapy and Oncology-Advisory Committee in Radiation Oncology Practice Consensus Guidelines for Target Volume Delineation. Clin Oncol (R Coll Radiol). 2021 Jan;33(1):20-29. doi: 10.1016/j.clon.2020.09.004. Epub 2020 Sep 26. PMID: 32988717.
 
34. Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauerc M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Španić T, Steyerova P, Tausch C, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol. 2021 Jan;22(1):e18-e28. doi: 10.1016/S1470-2045(20)30580-5. PMID: 33387500.
 
35. Machiels M, Kaidar-Person O, Rubio IT, Poortmans P. Local Treatment of Triple-Negative Breast Cancer. Cancer J. 2021 Jan-Feb 01;27(1):32-40. doi: 10.1097/PPO.0000000000000496. PMID: 33475291.
 
36. Corradini S, Niyazi M, Verellen D, Valentini V, Walsh S, Grosu AL, Lauber K, Giaccia A, Unger K, Debus J, Pieters BR, Guckenberger M, Senan S, Budach W, Rad R, Mayerle J, Belka C. X-change symposium: status and future of modern radiation oncology-from technology to biology. Radiat Oncol. 2021 Feb 4;16(1):27. doi: 10.1186/s13014-021-01758-w. PMID: 33541387; PMCID: PMC7863262.
 
37. Kaidar-Person O, Hermann N, Poortmans P, Offersen BV, Boersma LJ, de Ruysscher D, Tramm T, Kühn T, Engberg Damsgaard T, Gentilini O, Maarse W, Sklair-Levi M, Mátrai Z. A multidisciplinary approach for autologous breast reconstruction: A narrative (re)view for better management. Radiother Oncol. 2021 Feb 12;157:263-271. doi: 10.1016/j.radonc.2021.01.036. Epub ahead of print. PMID: 33582192.
 
38. Cardoso F, MacNeill F, Penault-Llorca F, Eniu A, Sardanelli F, Nordström EB, Poortmans P. Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto. Breast. 2021 Feb;55:128-135. doi: 10.1016/j.breast.2020.12.010. Epub 2021 Jan 2. PMID: 33461060; PMCID: PMC7817501.
 
39. Marazzi F, Masiello V, Masciocchi C, Merluzzi M, Saldi S, Belli P, Boldrini L, Capocchiano ND, Di Leone A, Magno S, Meldolesi E, Moschella F, Mulé A, Smaniotto D, Terribile DA, Tagliaferri L, Franceschini G, Gambacorta MA, Masetti R, Valentini V, Poortmans PMP, Aristei C. The Assisi Think Tank Meeting Breast Large Database for Standardized Data Collection in Breast Cancer-ATTM.BLADE. J Pers Med. 2021 Feb 19;11(2):143. doi: 10.3390/jpm11020143. PMID: 33669549; PMCID: PMC7926376.
 
40. Poortmans PM, Weltens C, Kirkove C; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Indications for individual internal mammary node irradiation - Authors' reply. Lancet Oncol. 2021 Feb;22(2):e41. doi: 10.1016/S1470-2045(21)00026-7. PMID: 33539748.
 
41. Kaidar-Person O, Offersen BV, Boersma LJ, de Ruysscher D, Tramm T, Kühn T, Gentilini O, Mátrai Z, Poortmans P. A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges. Breast. 2021 Feb 10;56:42-52. doi: 10.1016/j.breast.2021.02.004. Epub ahead of print. PMID: 33610903; PMCID: PMC7905468.
 
42. Machiels M, Weytjens R, Bauwens W, Vingerhoed W, Billiet C, Huget P, Verellen D, Dirix P, Meijnders P, Poortmans P, Kaidar-Person O. Accelerated Adaptation of Ultrahypofractionated Radiation Therapy for Breast Cancer at the Time of the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e166-e171. doi: 10.1016/j.clon.2020.11.027. Epub 2020 Dec 2. PMID: 33309183; PMCID: PMC7834150.
 
43. Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, Lenihan DJ, Marrazzo L, Curigliano G, Livi L. Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. JAMA Oncol. 2021 Mar 4. doi: 10.1001/jamaoncol.2020.7468. Epub ahead of print. PMID: 33662107.
 
44. Deschuymer S, Nevens D, Duprez F, Daisne JF, Voordeckers M, De Neve W, Nuyts S. Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. Qual Life Res. 2021 Jan;30(1):117-127. doi: 10.1007/s11136-020-02628-w. Epub 2020 Sep 13. PMID: 32920767.
 
45. Kayali M, Jaoude JA, Ramia P, Assi H, Geara F, Poortmans P, Zeidan YH. Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited. Ecancermedicalscience. 2021 Mar 1;15:1194. doi: 10.3332/ecancer.2021.1194. PMID: 33889203; PMCID: PMC8043677.
 
46. Cusumano D, Boldrini L, Dhont J, Fiorino C, Green O, Güngör G, Jornet N, Klüter S, Landry G, Mattiucci GC, Placidi L, Reynaert N, Ruggieri R, Tanadini-Lang S, Thorwarth D, Yadav P, Yang Y, Valentini V, Verellen D, Indovina L. Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and physical considerations on state of art and future perspectives. Phys Med. 2021 May;85:175-191. doi: 10.1016/j.ejmp.2021.05.010. Epub 2021 May 19. PMID: 34022660.
 
47. Vachon H, Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Fortpied C, Flechtner HH, Vestmoe Maraldo M, Hutchings M, Meijnders P, Aleman B, Lugtenburg P, Spina M, André M, Hertzberg M, Briones J, Bottomley A; EORTC Quality of Life Group, Lymphoma Group. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. Eur J Haematol. 2021 May;106(5):697-707. doi: 10.1111/ejh.13601. Epub 2021 Feb 28. PMID: 33570765.
 
 
48. Bertholet J, Aznar MC, Garibaldi C, Thwaites D, Gershkevitsh E, Thorwarth D, Verellen D, Heijmen B, Hurkmans C, Muren L, Redalen KR, Siebert FA, Schwarz M, Van Elmpt W, Georg D, Jornet N, Clark CH. Professional practice changes in radiotherapy physics during the COVID-19 pandemic. Phys Imaging Radiat Oncol. 2021 Jul;19:25-32. doi: 10.1016/j.phro.2021.06.002. Epub 2021 Jun 22. PMID: 34179522; PMCID: PMC8216850.
 
49. Spaas M, Sundahl N, Hulstaert E, Kruse V, Rottey S, De Maeseneer D, Surmont V, Meireson A, Brochez L, Reynders D, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Mestdagh P, Ost P. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer. 2021 May 7;21(1):514. doi: 10.1186/s12885-021-08088-w. PMID: 33962592; PMCID: PMC8106163.
 
50. Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262. PMID: 34066769; PMCID: PMC8125909.
 
51. Meireson A, Tavernier SJ, Van Gassen S, Sundahl N, Demeyer A, Spaas M, Kruse V, Ferdinande L, Van Dorpe J, Hennart B, Allorge D, Haerynck F, Decaestecker K, Rottey S, Saeys Y, Ost P, Brochez L. Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers (Basel). 2021 May 27;13(11):2630. doi: 10.3390/cancers13112630. PMID: 34071888; PMCID: PMC8198315.
 
52. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Erratum in: Lancet. 2021 May 8;397(10286):1710. PMID: 33812473.
 
53. Lumen N, De Bleser E, Buelens S, Verla W, Poelaert F, Claeys W, Fonteyne V, Verbeke S, Villeirs G, De Man K, Rottey S, Van Praet C, Decaestecker K, Ost P; LoMP Registry Investigators. The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. Eur Urol Open Sci. 2021 Jun 5;29:68-76. doi: 10.1016/j.euros.2021.05.006. PMID: 34337536; PMCID: PMC8317829.
 
54. Franco NR, Massi MC, Ieva F, Manzoni A, Paganoni AM, Zunino P, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Veldwijk MR, Herskind C, Avuzzi B, Noris Chiorda B, Valdagni R, Azria D, Farcy-Jacquet MP, Brengues M, Rosenstein BS, Stock RG, Vega A, Aguado-Barrera ME, Sosa-Fajardo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T; REQUITE Consortium Collaborators. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiother Oncol. 2021 Jun;159:241-248. doi: 10.1016/j.radonc.2021.03.024. Epub 2021 Apr 8. PMID: 33838170.
 
55. Wilkins A, Ost P, Sundahl N. Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer? Clin Oncol (R Coll Radiol). 2021 Jun;33(6):407-414. doi: 10.1016/j.clon.2021.02.014. Epub 2021 Mar 13. PMID: 33726945.
 
56. Offersen BV, Poortmans P. This house believes that all node positive breast cancer patients need post mastectomy radiation therapy. Eur J Surg Oncol. 2021 Jun 29:S0748-7983(21)00592-8. doi: 10.1016/j.ejso.2021.06.028. Epub ahead of print. PMID: 34215474.
 
57. Warren GW, Lim VS, Chowdhary M, Marwaha G, Abd Elbadee OM, Kirakli EK, Billiet C, Marin AG, Ramos M, Suppli MH, McGinnis GJ, Adjei AA. New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019. J Thorac Oncol. 2021 Jun 22:S1556-0864(21)02232-2. doi: 10.1016/j.jtho.2021.06.005. Epub ahead of print. PMID: 34166850; PMCID: PMC8216849.
 
58. Ost P, Siva S, Zilli T. Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS. Eur Urol. 2021 Jul 29:S0302-2838(21)01887-X. doi: 10.1016/j.eururo.2021.07.008. Epub ahead of print. PMID: 34334223.
 
59. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2021 Jul;16(7):1200-1210. doi: 10.1016/j.jtho.2021.03.019. Epub 2021 Apr 3. PMID: 33823286.
 
60. Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, Ost P, Rappe B, De Troyer B, Verbaeys C, Kimpe B, Billiet I, Plancke H, Fransis K, Willemen P, Ameye F, Decaestecker K, Lumen N. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553. Epub ahead of print. PMID: 34289231.
 
61. Jasu J, Tolonen T, Antonarakis ES, Beltran H, Halabi S, Eisenberger MA, Carducci MA, Loriot Y, Van der Eecken K, Lolkema M, Ryan CJ, Taavitsainen S, Gillessen S, Högnäs G, Talvitie T, Taylor RJ, Koskenalho A, Ost P, Murtola TJ, Rinta-Kiikka I, Tammela T, Auvinen A, Kujala P, Smith TJ, Kellokumpu-Lehtinen PL, Isaacs WB, Nykter M, Kesseli J, Bova GS. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021 Jul 2;30:47-62. doi: 10.1016/j.euros.2021.05.011. PMID: 34337548; PMCID: PMC8317817.
 
62. Psutka SP, Morgan T, Albersen M, Cornu JN, Novara G, Plimack E, Ost P, Catto JWF. The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. Eur Urol. 2021 Jul 17:S0302-2838(21)01869-8. doi: 10.1016/j.eururo.2021.07.002. Epub ahead of print. PMID: 34284917.
 
Kaidar-Person O, Poortmans P. Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial. Lancet Oncol. 2021 Jul;22(7):e294. doi: 10.1016/S1470-2045(21)00259-X. PMID: 34197755.
 
63. Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM, Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T, Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treat Rev. 2021 Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. PMID: 33965893.
 
64. Spaas M, Van den Broeck B, Creytens D, Kruse V, Ost P. Spatiotemporal Evolution of Radiation Myositis on 18F-FDG PET/CT Following Hypofractionated Radiotherapy of Intramuscular Melanoma Metastases. Clin Nucl Med. 2021 Jul 1;46(7):e384-e386. doi: 10.1097/RLU.0000000000003596. PMID: 33782297.
 
65. Kayali M, Abi Jaoude J, Mohammed M, Khabsa J, Tfayli A, Poortmans P, Zeidan YH. Post-mastectomy Radiation Therapy in Triple-Negative Breast Cancer Patients: Analysis of the BEATRICE Trial. Ann Surg Oncol. 2021 Jul 29. doi: 10.1245/s10434-021-10511-2. Epub ahead of print. PMID: 34324113.
 
66. Poortmans PM, Struikmans H, De Brouwer P, Weltens C, Fortpied C, Kirkove C, Budach V, Peignaux-Casasnovas K, van der Leij F, Vonk E, Valli M, van Tienhoven G, Weidner N, Noel G, Guckenberger M, Koiter E, van Limbergen E, Engelen A, Fourquet A, Bartelink H; EORTC Radiation Oncology and Breast Cancer Groups. Side Effects 15 Years after Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925. J Natl Cancer Inst. 2021 Jul 28:djab113. doi: 10.1093/jnci/djab113. Epub ahead of print. PMID: 34320651.
 
67. Kaidar-Person O, Offersen BV, Boersma L, Meattini I, Dodwell D, Wyld L, Aznar M, Major T, Kuehn T, Strnad V, Palmu M, Hol S, Poortmans P. Tricks and tips for target volume definition and delineation in breast cancer: Lessons learned from ESTRO breast courses. Radiother Oncol. 2021 Jul 21;162:185-194. doi: 10.1016/j.radonc.2021.07.015. Epub ahead of print. PMID: 34302915.
 
68. Vrieling C, Assele SY, Moser L, Sauvé N, Litière S, Fourquet A, Poortmans P, Struikmans H, van Tienhoven G, Bartelink H, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. Eur J Cancer. 2021 Jul 29;155:28-37. doi: 10.1016/j.ejca.2021.06.018. Epub ahead of print. PMID: 34333446.
 
69. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 Jul 6:S0923-7534(21)02104-9. doi: 10.1016/j.annonc.2021.06.023. Epub ahead of print. PMID: 34242744.
 
70. Dahn HM, Boersma LJ, de Ruysscher D, Meattini I, Offersen BV, Pignol JP, Aristei C, Belkacemi Y, Benjamin D, Bese N, Coles CE, Franco P, Ho A, Hol S, Jagsi R, Kirby AM, Marrazzo L, Marta GN, Moran MS, Nichol AM, Nissen HD, Strnad V, Zissiadis YE, Poortmans P, Kaidar-Person O. The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review. Crit Rev Oncol Hematol. 2021 Jul;163:103391. doi: 10.1016/j.critrevonc.2021.103391. Epub 2021 Jun 5. PMID: 34102286.
 
71. Kaidar-Person O, Poortmans P, Salgado R. Genomic-adjusted radiation dose to personalise radiotherapy. Lancet Oncol. 2021 Aug 4:S1470-2045(21)00411-3. doi: 10.1016/S1470-2045(21)00411-3. Epub ahead of print. PMID: 34363760.
 
72. De Caluwé A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Stylianos D, Vandekerckhove C, Reyal F, Isabelle V, Eiger D, Piccart M, Romano E, Ignatiadis M. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. BMC Cancer. 2021 Aug 6;21(1):899. doi: 10.1186/s12885-021-08601-1. PMID: 34362344; PMCID: PMC8343924.
 
73. Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021 Aug;22(8):1139-1150. doi: 10.1016/S1470-2045(21)00288-6. PMID: 34339645; PMCID: PMC8324484.
 
74. Tramm T, Christiansen P, Offersen BV, Madsen KB, Poortmans P, Kaidar-Person O. Superficial margins in skin sparing and nipple sparing mastectomies for DCIS: A margin of potential concern. Radiother Oncol. 2021 Aug;161:177-182. doi: 10.1016/j.radonc.2021.06.018. Epub 2021 Jun 15. PMID: 34139212.
 
75. Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Gomez S, Wust P, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol. 2021 Sep;80(3):306-315. doi: 10.1016/j.eururo.2021.05.033. Epub 2021 Jun 14. PMID: 34140144.
 
76. Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treat Rev. 2021 Sep;99:102208. doi: 10.1016/j.ctrv.2021.102208. Epub 2021 Apr 20. PMID: 34238640.
 
77. Kaidar-Person O, Dahn HM, Nichol AM, Boersma LJ, de Ruysscher D, Meattini I, Pignol JP, Aristei C, Belkacemi Y, Benjamin D, Bese N, Coles CE, Franco P, Ho AY, Hol S, Jagsi R, Kirby AM, Marrazzo L, Marta GN, Moran MS, Nissen HD, Strnad V, Zissiadis Y, Poortmans PM, Offersen BV. A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiother Oncol. 2021 Sep 24;164:115-121. doi: 10.1016/j.radonc.2021.09.012. Epub ahead of print. PMID: 34563607.
 
78. Senkus E, Cardoso MJ, Kaidar-Person O, Łacko A, Meattini I, Poortmans P. De-escalation of axillary irradiation for early breast cancer - Has the time come? Cancer Treat Rev. 2021 Oct 8;101:102297. doi: 10.1016/j.ctrv.2021.102297. Epub ahead of print. PMID: 34656018.
 
79. Gómez-Aparicio MA, Valero J, Caballero B, García R, Hernando-Requejo O, Montero Á, Gómez-Iturriaga A, Zilli T, Ost P, López-Campos F, Couñago F. Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Curr Oncol. 2021 Aug 3;28(4):2933-2949. doi: 10.3390/curroncol28040257. PMID: 34436023; PMCID: PMC8395496.
 
80. Siva S, Ost P, Zaorsky N, Staehler M. Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. Eur Urol. 2021 Sep 23:S0302-2838(21)02001-7. doi: 10.1016/j.eururo.2021.09.006. Epub ahead of print. PMID: 34563413.
 
81. Verghote F, Poppe L, Verbeke S, Dirix P, Albersen M, De Meerleer G, Berghen C, Ost P, Villeirs G, De Visschere P, De Man K, De Maeseneer D, Rottey S, Van Praet C, Decaestecker K, Fonteyne V. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. BMC Cancer. 2021 Oct 18;21(1):1113. doi: 10.1186/s12885-021-08861-x. PMID: 34663254; PMCID: PMC8522089.
 
82. Bossi P, Trama A, Bernasconi A, Grisanti S, Mohamad I, Galiana IL, Ozyar E, Franco P, Vecchio S, Bonomo P, Cirauqui BC, El-Sherify M, Ursino S, Argiris A, Pan J, Wittekindt C, D'Angelo E, Costa L, Buglione M, Johnson J, Airoldi M, Mesia R, Resteghini C, Licitra L, Orlandi E; Nasopharyngeal Cancer Portal Group of Investigators. Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. Eur J Cancer. 2021 Nov 10;159:194-204. doi: 10.1016/j.ejca.2021.09.005. Epub ahead of print. PMID: 34773903.
 
83. Marcuse F, Peeters S, Herman K, Vaassen F, van Elmpt W, Maat APWM, Praag J, Billiet C, Van Schil P, Lambrecht M, Van Raemdonck D, Cao K, Grigoroiu M, Girard N, Hochstenbag M, Maessen J, De Ruysscher D. Optimal delineation of the clinical target volume for thymomas in the post-resection setting: A multi-center study. Radiother Oncol. 2021 Oct 18;165:8-13. doi: 10.1016/j.radonc.2021.10.007. Epub ahead of print. PMID: 34673091.
 
84. El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355; PMCID: PMC8636568.
 
85. Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. Cancer Treat Rev. 2022 Feb;103:102324. doi: 10.1016/j.ctrv.2021.102324. Epub 2021 Dec 16. PMID: 34953200.
 
86. Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C, Brunt AM, Dicuonzo S, Franco P, Krause M, MacKenzie M, Marinko T, Marrazzo L, Ratosa I, Scholten A, Senkus E, Stobart H, Poortmans P, Coles CE. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022 Jan;23(1):e21-e31. doi: 10.1016/S1470-2045(21)00539-8. PMID: 34973228.
 
87. Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab. Int J Radiat Oncol Biol Phys. 2022 Jan 2:S0360-3016(21)03432-5. doi: 10.1016/j.ijrobp.2021.12.159. Epub ahead of print. PMID: 34986381.
 
88. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. PMID: 35123662; PMCID: PMC8885431.
 
89. Marta GN, Riera R, Pacheco RL, Cabrera Martimbianco AL, Meattini I, Kaidar-Person O, Poortmans P. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials. Breast. 2022 Feb 3;62:84-92. doi: 10.1016/j.breast.2022.01.018. Epub ahead of print. PMID: 35131647.
 
90. Coles CE, Anderson BO, Cameron D, Cardoso F, Horton R, Knaul FM, Mutebi M, Lee N; Lancet Breast Cancer Commission. The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge. Lancet. 2022 Feb 18:S0140-6736(22)00184-2. doi: 10.1016/S0140-6736(22)00184-2. Epub ahead of print. PMID: 35189077.
 
91. Kaidar-Person O, Yoeli-Ullman R, Pillar N, Paluch-Shimon S, Poortmans P, Lawrence YR. Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study. Breast. 2022 Feb 15;62:170-178. doi: 10.1016/j.breast.2022.02.008. Epub ahead of print. PMID: 35219114; PMCID: PMC8873951.
 
92. Van der Eecken K, Vanwelkenhuyzen J, Deek MP, Tran PT, Warner E, Wyatt AW, Kwan EM, Verbeke S, Van Dorpe J, Fonteyne V, Lumen N, De Laere B, Ost P. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2021 Dec;4(6):914-923. doi: 10.1016/j.euo.2021.10.005. Epub 2021 Nov 17. PMID: 34801437.
 
93. Spaas M, Sundahl N, Ost P. Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022 Feb;81(2):216. doi: 10.1016/j.eururo.2021.11.003. Epub 2021 Nov 20. PMID: 34810013.
 
94. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S; APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 Jan;160:24-60. doi: 10.1016/j.ejca.2021.09.036. Epub 2021 Nov 26. PMID: 34844839.
 
95. Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, Liefhooghe N, Noé L, De Meerleer G, Ost P, Villeirs G, Verbeke S, De Maeseneer D, Rammant E, Verghote F, Elhaseen E, De Man K, Decaestecker K. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. Eur Urol Focus. 2021 Dec 7:S2405-4569(21)00304-7. doi: 10.1016/j.euf.2021.11.004. Epub ahead of print. PMID: 34893458.
 
96. Beck M, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Hayoz S, Schär C, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Aebersold DM, Ghadjar P, Pra AD; Swiss Group for Clinical Cancer Research. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. Int J Radiat Oncol Biol Phys. 2022 Jan 3:S0360-3016(21)03447-7. doi: 10.1016/j.ijrobp.2021.12.174. Epub ahead of print. PMID: 34990777.
 
97. Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan T, Mendes AA, Paller CJ, Carducci MA, Ross A, Wang H, Pienta K, Feng FY, Antonarakis ES, Ost P, Song DY, Greco S, Deville C, DeWeese T, Tran PT, Deek MP. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. 2022 Jan 11. doi: 10.1038/s41391-021-00484-4. Epub ahead of print. PMID: 35013522.
 
98. Mercier C, Strijbos M, Ost P. Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy. Eur Urol. 2022 Jan 18:S0302-2838(22)00002-1. doi: 10.1016/j.eururo.2022.01.001. Epub ahead of print. PMID: 35063309.
 
99. Gómez-Aparicio MA, López-Campos F, Pelari-Mici L, Buchser D, Pastor J, Maldonado X, Zafra J, Tree AC, Bultijnck R, Sargos P, Ost P, Couñago F. Bone health and therapeutic agents in advanced prostate cancer. Front Biosci (Landmark Ed). 2022 Jan 18;27(1):34. doi: 10.31083/j.fbl2701034. PMID: 35090339.
 
100. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, Parent MÉ, Hu JJ, Zheng W; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium, Mills IG, Andreassen OA, Dale AM, Seibert TM. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022 Feb 12. doi: 10.1038/s41391-022-00497-7. Epub ahead of print. PMID: 35152271.
 
101. Strijbos M, Van den Mooter T, Ost P. New targets, new hopes. ESMO Open. 2022 Mar 2;7(2):100420. doi: 10.1016/j.esmoop.2022.100420. Epub ahead of print. PMID: 35248825.
 
102. Marinelli M, Felici G, Galante F, Gasparini A, Giuliano L, Heinrich S, Pacitti M, Prestopino G, Vanreusel V, Verellen D, Verona C, Verona Rinati G. Design, realization, and characterization of a novel diamond detector prototype for FLASH radiotherapy dosimetry. Med Phys. 2022 Jan 21. doi: 10.1002/mp.15473. Epub ahead of print. PMID: 35064594.
 
103. Garibaldi C, Essers M, Heijmen B, Bertholet J, Koutsouveli E, Schwarz M, Bert C, Bodale M, Casares-Magaz O, Gerskevitch E, Koniarova I, Korreman S, Lisbona A, Lopez Medina A, Maas A, Moeckli R, Moore M, Petrovic B, Piotrowski T, Poli E, Prezado Y, Reynaert N, Røe Redalen K, Stylianou Markidou E, Verellen D, Jornet N, Clark CH. The 3rd ESTRO-EFOMP core curriculum for medical physics experts in radiotherapy. Radiother Oncol. 2022 Feb 18:S0167-8140(22)00097-4. doi: 10.1016/j.radonc.2022.02.012. Epub ahead of print. PMID: 35189156.
 
104. Ghita M, Billiet C, Copot D, Verellen D, Ionescu CM. Model Calibration of Pharmacokinetic-Pharmacodynamic Lung Tumour Dynamics for Anticancer Therapies. J Clin Med. 2022 Feb 15;11(4):1006. doi: 10.3390/jcm11041006. PMID: 35207279; PMCID: PMC8879872.
 
105. Verbanck S, Van Parijs H, Schuermans D, Vinh-Hung V, Storme G, Fontaine C, De Ridder M, Verellen D, Vanderhelst E, Hanon S. Lung Restriction in Breast Cancer Patients after Hypofractionated Tomotherapy and Conventional 3D Conformal Radiotherapy: a 10-year Follow-up. Int J Radiat Oncol Biol Phys. 2022 Feb 25:S0360-3016(22)00167-5. doi: 10.1016/j.ijrobp.2022.02.021. Epub ahead of print. PMID: 35227790.
 
106. Klinghammer K, Lorini L, Nevens D, Simon C, Machiels JP, Bossi P. Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. Front Oncol. 2022 Jan 27;12:730785. doi: 10.3389/fonc.2022.730785. PMID: 35155222; PMCID: PMC8830482.
 
107. Montay-Gruel P, Corde S, Laissue JA, Bazalova-Carter M. FLASH radiotherapy with photon beams. Med Phys. 2021 Sep 14. doi: 10.1002/mp.15222. Epub ahead of print. PMID: 34519042.
 
108. Fiagan YAC, Bossuyt E, Machiels M, Nevens D, Billiet C, Poortmans P, Gevaert T, Verellen D. Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry. Phys Imaging Radiat Oncol. 2022 May 13;22:85-90. doi: 10.1016/j.phro.2022.05.003. PMID: 35602547; PMCID: PMC9117915.
 
109. Billiet C, Vingerhoed W, Van Laere S, Joye I, Mercier C, Dirix P, Nevens D, Vermeulen P, Meijnders P, Verellen D. Precision of image-guided spinal stereotactic ablative radiotherapy and impact of positioning variables. Phys Imaging Radiat Oncol. 2022 May 5;22:73-76. doi: 10.1016/j.phro.2022.04.006. PMID: 35686020; PMCID: PMC9172170.
 
110. Nevens D, Jongen A, Kindts I, Billiet C, Deseyne P, Joye I, Lievens Y, Guckenberger M. Completeness of reporting oligometastatic disease characteristics in literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature. Int J Radiat Oncol Biol Phys. 2022 Jun 20:S0360-3016(22)00612-5. doi: 10.1016/j.ijrobp.2022.06.067. Epub ahead of print. PMID: 35738308.
 
111. Allaeys T, Berzenji L, Lauwers P, Yogeswaran SK, Hendriks JMH, Billiet C, De Bondt C, Van Schil PE. Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2022 Mar 25;14(7):1656. doi: 10.3390/cancers14071656. PMID: 35406428; PMCID: PMC8997106.
 
112. Van den Brande R, Mj Cornips E, Peeters M, Ost P, Billiet C, Van de Kelft E. Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review. J Bone Oncol. 2022 Jul 9;35:100446. doi: 10.1016/j.jbo.2022.100446. PMID: 35860387; PMCID: PMC9289863.
 
113. Latacz E, Höppener D, Bohlok A, Leduc S, Tabariès S, Fernández Moro C, Lugassy C, Nyström H, Bozóky B, Floris G, Geyer N, Brodt P, Llado L, Van Mileghem L, De Schepper M, Majeed AW, Lazaris A, Dirix P, Zhang Q, Petrillo SK, Vankerckhove S, Joye I, Meyer Y, Gregorieff A, Roig NR, Vidal-Vanaclocha F, Denis L, Oliveira RC, Metrakos P, Grünhagen DJ, Nagtegaal ID, Mollevi DG, Jarnagin WR, D'Angelica MI, Reynolds AR, Doukas M, Desmedt C, Dirix L, Donckier V, Siegel PM, Barnhill R, Gerling M, Verhoef C, Vermeulen PB. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br J Cancer. 2022 Jun 1. doi: 10.1038/s41416-022-01859-7. Epub ahead of print. PMID: 35650276.
 
114. Danckaert W, Spaas M, Vandecasteele K, De Wagter C, Ost P. Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literature. Radiother Oncol. 2022 May;170:64-69. doi: 10.1016/j.radonc.2022.02.030. Epub 2022 Mar 4. PMID: 35257847.
 
115. De Laere B, Crippa A, Discacciati A, Larsson B, Oldenburg J, Mortezavi A, Ost P, Eklund M, Lindberg J, Grönberg H; ProBio Investigators. Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. Eur Urol Focus. 2022 Mar 19:S2405-4569(22)00060-8. doi: 10.1016/j.euf.2022.03.005. Epub ahead of print. PMID: 35317973.
 
116. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. Erratum in: Eur Urol. 2022 Apr 16;: PMID: 35393158; PMCID: PMC8849852.
 
117. De Man K, Piron S, Van Laeken N, Delrue L, Fonteyne V, Lumen N, Van den Broeck B, Kersemans K, Ost P, Schelfhout V. Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. Mol Imaging Biol. 2022 Apr 11. doi: 10.1007/s11307-022-01724-2. Epub ahead of print. PMID: 35411446.
 
 118. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul;82(1):115-141. doi: 10.1016/j.eururo.2022.04.002. Epub 2022 Apr 18. PMID: 35450732.
 
119. Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. PMID: 35476942.
 
120. Mercier C, Claessens M, De Troyer B, Debacker T, Fransis K, Vandeursen H, Ost P, Dirix P. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer. Front Oncol. 2022 Apr 14;12:863609. doi: 10.3389/fonc.2022.863609. PMID: 35494057; PMCID: PMC9046565.
 
121. Fonseca NM, Van der Eecken K, Herberts C, Verbeke S, Ng SWS, Lumen N, Ritch E, Murtha AJ, Bernales CQ, Schönlau E, Moris L, Van Dorpe J, Annala M, Wyatt AW, Ost P. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precis Oncol. 2022 Apr;6:e2100543. doi: 10.1200/PO.21.00543. PMID: 35507889.
 
122. Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate. 2022 Aug;82 Suppl 1(Suppl 1):S73-S85. doi: 10.1002/pros.24373. PMID: 35657158; PMCID: PMC9202472.
 
123. Barry AS, Helou J, Bezjak A, Wong R, Dawson LA, Ringash J, Fazelzad R, Liu Z, Olson R, Palma D, Ost P, Siva S, Phillips R, Adhikari NKJ. Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis. Radiother Oncol. 2022 Aug;173:163-169. doi: 10.1016/j.radonc.2022.05.033. Epub 2022 Jun 6. PMID: 35680076.
 
124. De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022 Jun 8:S0302-2838(22)02383-1. doi: 10.1016/j.eururo.2022.05.010. Epub ahead of print. PMID: 35690515.
 
125. Van den Brande R, Mj Cornips E, Peeters M, Ost P, Billiet C, Van de Kelft E. Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review. J Bone Oncol. 2022 Jul 9;35:100446. doi: 10.1016/j.jbo.2022.100446. PMID: 35860387; PMCID: PMC9289863.
 
126. Gómez F, Gonzalez-Castaño DM, Fernández NG, Pardo-Montero J, Schüller A, Gasparini A, Vanreusel V, Verellen D, Felici G, Kranzer R, Paz-Martín J. Development of an ultra-thin parallel plate ionization chamber for dosimetry in FLASH radiotherapy. Med Phys. 2022 Jul;49(7):4705-4714. doi: 10.1002/mp.15668. Epub 2022 Apr 22. PMID: 35416306.
 
127. Claessens M, Vanreusel V, De Kerf G, Mollaert I, Löfman F, Gooding MJ, Brouwer C, Dirix P, Verellen D. Machine learning-based detection of aberrant deep learning segmentations of target and organs at risk for prostate radiotherapy using a secondary segmentation algorithm. Phys Med Biol. 2022 May 27;67(11). doi: 10.1088/1361-6560/ac6fad. PMID: 35561701.
 
128. Verona Rinati G, Felici G, Galante F, Gasparini A, Kranzer R, Mariani G, Pacitti M, Prestopino G, Schüller A, Vanreusel V, Verellen D, Verona C, Marinelli M. Application of a novel diamond detector for commissioning of FLASH radiotherapy electron beams. Med Phys. 2022 Jun 2. doi: 10.1002/mp.15782. Epub ahead of print. PMID: 35652248.
 
129. Struikmans H, Mast ME, Petoukhova AL, Poortmans PM. In Regard to Mutter et al. Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1288-1289. doi: 10.1016/j.ijrobp.2021.12.156. PMID: 35286883.
 
130. Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V, Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast. 2022 Jun;63:123-139. doi: 10.1016/j.breast.2022.03.008. Epub 2022 Mar 18. PMID: 35366506; PMCID: PMC8976143.
 
131. Kaidar-Person O, Poortmans P. Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction. Lancet Oncol. 2022 May;23(5):560-562. doi: 10.1016/S1470-2045(22)00195-4. Epub 2022 Apr 7. PMID: 35397802.
 
132. Neven A, van Maaren MC, Schreuder K, Kranse R, Struikmans H, Poortmans PM, Bartelink H, Collette L, Liu L, Siesling S. Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry. J Clin Epidemiol. 2022 Apr 15;148:54-64. doi: 10.1016/j.jclinepi.2022.04.014. Epub ahead of print. PMID: 35436524.
 
133. Lawler M, Oliver K, Gijssels S, Aapro M, Abolina A, Albreht T, Erdem S, Geissler J, Jassem J, Karjalainen S, La Vecchia C, Lievens Y, Meunier F, Morrissey M, Naredi P, Oberst S, Poortmans P, Price R, Sullivan R, Velikova G, Vrdoljak E, Wilking N, Yared W, Selby P. The European Code of Cancer Practice. J Cancer Policy. 2021 Jun;28:100282. doi: 10.1016/j.jcpo.2021.100282. Epub 2021 Apr 19. PMID: 35559911.
 
134. Kaidar-Person O, Fortpied C, Hol S, Weltens C, Kirkove C, Budach V, Peignaux-Casasnovas K, van der Leij F, Vonk E, Valli M, Weidner N, Guckenberger M, Koiter E, Fourquet A, Bartelink H, Struikmans H, Poortmans P; EORTC Radiation Oncology and Breast Cancer Groups. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial. Radiother Oncol. 2022 Jul;172:99-110. doi: 10.1016/j.radonc.2022.05.006. Epub 2022 May 12. PMID: 35568284.
 
135. Bogers SLC, Petoukhova AL, Penninkhof JJ, Mast ME, Poortmans PM, Hoogeman MS, Struikmans H. Target Volume Coverage and Organ at Risk Doses for Left-sided Whole-breast Irradiation With or Without Internal Mammary Chain Irradiation: A Comparison Between Three Techniques Representing the Past and the Present. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):537-544. doi: 10.1016/j.clon.2022.04.004. Epub 2022 May 21. PMID: 35606251.
 
136. Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F. Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001. Epub 2022 May 9. PMID: 35644793.
 
137. Kaidar-Person O, Weber WP, Kühn T, Poortmans P. The forgotten node: Axillary surgery mandates expertise. Eur J Surg Oncol. 2022 May 17:S0748-7983(22)00437-1. doi: 10.1016/j.ejso.2022.05.012. Epub ahead of print. PMID: 35654700.
 
138. Heimovaara JH, Boere IA, de Haan J, van Calsteren K, Amant F, van Zuylen L, Lok CAR; Dutch Advisory Board for Cancer during Pregnancy. Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands. Eur J Cancer. 2022 Aug;171:13-21. doi: 10.1016/j.ejca.2022.04.040. Epub 2022 Jun 10. PMID: 35696885.
 
139. Fastner G, Krug D, Meattini I, Gruber G, Poortmans P. Expert Discussion: Hypofractionated Radiation Therapy - Standard for All Indications? Breast Care (Basel). 2022 Apr;17(2):224-231. doi: 10.1159/000521552. Epub 2021 Dec 20. PMID: 35707177; PMCID: PMC9149542.
 
140. Gasparri ML, de Boniface J, Poortmans P, Gentilini OD, Kaidar-Person O, Banys-Paluchowski M, Di Micco R, Niinikoski L, Murawa D, Bonci EA, Pasca A, Rubio IT, Karadeniz Cakmak G, Kontos M, Kühn T. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022 Jun 29:znac217. doi: 10.1093/bjs/znac217. Epub ahead of print. PMID: 35766257.
 
141. Aristei C, Bölükbaşı Y, Kaidar-Person O, Pfeffer R, Arenas M, Boersma LJ, Ciabattoni A, Coles CE, Franco P, Krengli M, Leonardi MC, Marazzi F, Masiello V, Meattini I, Montero A, Offersen B, Trigo ML, Bourgier C, Genovesi D, Kouloulias V, Morganti AG, Meduri B, Pasinetti N, Pedretti S, Perrucci E, Rivera S, Tombolini V, Vidali C, Valentini V, Poortmans P. Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. Crit Rev Oncol Hematol. 2022 Jul 30;177:103774. doi: 10.1016/j.critrevonc.2022.103774. Epub ahead of print. PMID: 35917884.
 
142. Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi-Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Gentilini O, Harbeck N, Kaufman B, Kim SB, Liu Q, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Sirohi B, Spanic T, Sulosaari V, Peccatori F, Pagani O. ESO-ESMO 5th International Consensus Guidelines for Breast Cancer in Young Women (BCY5). Ann Oncol. 2022 Aug 4:S0923-7534(22)01858-0. doi: 10.1016/j.annonc.2022.07.007. Epub ahead of print. PMID: 35934170.
 
143. Verghote F, Sargos P, Christodouleas JP, Murthy V, Baumann BC, Dirix P, Berghen C, Paelinck L, Vercauteren T, Fonteyne V. International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup. Pract Radiat Oncol. 2022 Jun 9:S1879-8500(22)00190-4. doi: 10.1016/j.prro.2022.05.014. Epub ahead of print. PMID: 35691550.
 
144. Gómez F, Gonzalez-Castaño DM, Fernández NG, Pardo-Montero J, Schüller A, Gasparini A, Vanreusel V, Verellen D, Felici G, Kranzer R, Paz-Martín J. Development of an ultra-thin parallel plate ionization chamber for dosimetry in FLASH radiotherapy. Med Phys. 2022 Jul;49(7):4705-4714. doi: 10.1002/mp.15668. Epub 2022 Apr 22. PMID: 35416306; PMCID: PMC9545838.
 
145. Claessens M, Vanreusel V, De Kerf G, Mollaert I, Löfman F, Gooding MJ, Brouwer C, Dirix P, Verellen D. Machine learning-based detection of aberrant deep learning segmentations of target and organs at risk for prostate radiotherapy using a secondary segmentation algorithm. Phys Med Biol. 2022 May 27;67(11). doi: 10.1088/1361-6560/ac6fad. PMID: 35561701.
 
146. Fiagan YAC, Bossuyt E, Machiels M, Nevens D, Billiet C, Poortmans P, Gevaert T, Verellen D. Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry. Phys Imaging Radiat Oncol. 2022 May 13;22:85-90. doi: 10.1016/j.phro.2022.05.003. PMID: 35602547; PMCID: PMC9117915.
 
147. Verona Rinati G, Felici G, Galante F, Gasparini A, Kranzer R, Mariani G, Pacitti M, Prestopino G, Schüller A, Vanreusel V, Verellen D, Verona C, Marinelli M. Application of a novel diamond detector for commissioning of FLASH radiotherapy electron beams. Med Phys. 2022 Aug;49(8):5513-5522. doi: 10.1002/mp.15782. Epub 2022 Jun 16. PMID: 35652248; PMCID: PMC9543846.
 
148. Di Martino F, Del Sarto D, Giuseppina Bisogni M, Capaccioli S, Galante F, Gasperini A, Linsalata S, Mariani G, Pacitti M, Paiar F, Ursino S, Vanreusel V, Verellen D, Felici G. A new solution for UHDP and UHDR (Flash) measurements: Theory and conceptual design of ALLS chamber. Phys Med. 2022 Oct;102:9-18. doi: 10.1016/j.ejmp.2022.08.010. Epub 2022 Aug 27. PMID: 36030665.
 
149.  De Kerf G, Claessens M, Mollaert I, Vingerhoed W, Verellen D. Machine learning-based treatment couch parameter prediction in support of surface guided radiation therapy. Tech Innov Patient Support Radiat Oncol. 2022 Aug 12;23:15-20. doi: 10.1016/j.tipsro.2022.08.001. PMID: 36039333; PMCID: PMC9418545.
 
150. Claessens M, Oria CS, Brouwer CL, Ziemer BP, Scholey JE, Lin H, Witztum A, Morin O, Naqa IE, Van Elmpt W, Verellen D. Quality Assurance for AI-Based Applications in Radiation Therapy. Semin Radiat Oncol. 2022 Oct;32(4):421-431. doi: 10.1016/j.semradonc.2022.06.011. PMID: 36202444.
 
151. Eriksen JG, Boldrini L, Gershkevitsh E, Guckenberger M, van der Heide U, Heijmen B, Joiner M, Nout R, Pruschy M, Rasch C, Tan LT, Verellen D, Vozenin MC, Palmu M, La Porta L, Gasparotto C; ESTRO School. Postgraduate education in radiation oncology during the COVID-19 pandemic - What did we learn? Tech Innov Patient Support Radiat Oncol. 2022 Oct 12;24:73-77. doi: 10.1016/j.tipsro.2022.09.008. PMID: 36247369; PMCID: PMC9554011.
 
152. Vanreusel V, Gasparini A, Galante F, Mariani G, Pacitti M, Cociorb M, Giammanco A, Reniers B, Reulens N, Shonde TB, Vallet H, Vandenbroucke D, Peeters M, Leblans P, Ma B, Felici G, Verellen D, de Freitas Nascimento L. Point scintillator dosimetry in ultra-high dose rate electron "FLASH" radiation therapy: A first characterization. Phys Med. 2022 Nov;103:127-137. doi: 10.1016/j.ejmp.2022.10.005. Epub 2022 Oct 24. PMID: 36302279.
 
153. Di Martino F, Del Sarto D, Barone S, Giuseppina Bisogni M, Capaccioli S, Galante F, Gasparini A, Mariani G, Masturzo L, Montefiori M, Pacitti M, Paiar F, Harold Pensavalle J, Romano F, Ursino S, Vanreusel V, Verellen D, Felici G. A new calculation method for the free electron fraction of an ionization chamber in the ultra-high-dose-per-pulse regimen. Phys Med. 2022 Nov;103:175-180. doi: 10.1016/j.ejmp.2022.11.001. Epub 2022 Nov 9. PMID: 36370686.
 
154. Ghita M, Billiet C, Copot D, Verellen D, Ionescu CM. Parameterisation of Respiratory Impedance in Lung Cancer Patients from Forced Oscillation Lung Function Test. IEEE Trans Biomed Eng. 2022 Nov 17;PP. doi: 10.1109/TBME.2022.3222942. Epub ahead of print. PMID: 36395128.
 
155. de Freitas Nascimento L, Leblans P, van der Heyden B, Akselrod M, Goossens J, Correa Rocha LE, Vaniqui A, Verellen D. Characterisation and Quenching Correction for an Al2O3:C Optical Fibre Real Time System in Therapeutic Proton, Helium, and Carbon-Charged Beams. Sensors (Basel). 2022 Nov 25;22(23):9178. doi: 10.3390/s22239178. PMID: 36501879; PMCID: PMC9737660.
 
156. Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M. Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients. Cancers (Basel). 2022 Dec 18;14(24):6241. doi: 10.3390/cancers14246241. PMID: 36551726; PMCID: PMC9777311.
 
157. Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V, Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast. 2022 Jun;63:123-139. doi: 10.1016/j.breast.2022.03.008. Epub 2022 Mar 18. PMID: 35366506; PMCID: PMC8976143.
 
158. Kaidar-Person O, Poortmans P. Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction. Lancet Oncol. 2022 May;23(5):560-562. doi: 10.1016/S1470-2045(22)00195-4. Epub 2022 Apr 7. PMID: 35397802.
 
159. Neven A, van Maaren MC, Schreuder K, Kranse R, Struikmans H, Poortmans PM, Bartelink H, Collette L, Liu L, Siesling S. Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry. J Clin Epidemiol. 2022 Aug;148:54-64. doi: 10.1016/j.jclinepi.2022.04.014. Epub 2022 Apr 15. PMID: 35436524.
 
160. Lawler M, Oliver K, Gijssels S, Aapro M, Abolina A, Albreht T, Erdem S, Geissler J, Jassem J, Karjalainen S, La Vecchia C, Lievens Y, Meunier F, Morrissey M, Naredi P, Oberst S, Poortmans P, Price R, Sullivan R, Velikova G, Vrdoljak E, Wilking N, Yared W, Selby P. The European Code of Cancer Practice. J Cancer Policy. 2021 Jun;28:100282. doi: 10.1016/j.jcpo.2021.100282. Epub 2021 Apr 19. PMID: 35559911.
 
161. Kaidar-Person O, Fortpied C, Hol S, Weltens C, Kirkove C, Budach V, Peignaux-Casasnovas K, van der Leij F, Vonk E, Valli M, Weidner N, Guckenberger M, Koiter E, Fourquet A, Bartelink H, Struikmans H, Poortmans P; EORTC Radiation Oncology and Breast Cancer Groups. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial. Radiother Oncol. 2022 Jul;172:99-110. doi: 10.1016/j.radonc.2022.05.006. Epub 2022 May 12. PMID: 35568284.
 
162. Bogers SLC, Petoukhova AL, Penninkhof JJ, Mast ME, Poortmans PM, Hoogeman MS, Struikmans H. Target Volume Coverage and Organ at Risk Doses for Left-sided Whole-breast Irradiation With or Without Internal Mammary Chain Irradiation: A Comparison Between Three Techniques Representing the Past and the Present. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):537-544. doi: 10.1016/j.clon.2022.04.004. Epub 2022 May 21. PMID: 35606251.
 
163. Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F. Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001. Epub 2022 May 9. PMID: 35644793.
 
164. Kaidar-Person O, Weber WP, Kühn T, Poortmans P. The forgotten node: Axillary surgery mandates expertise. Eur J Surg Oncol. 2022 Sep;48(9):1922-1924. doi: 10.1016/j.ejso.2022.05.012. Epub 2022 May 17. PMID: 35654700.
 
165. Heimovaara JH, Boere IA, de Haan J, van Calsteren K, Amant F, van Zuylen L, Lok CAR; Dutch Advisory Board for Cancer during Pregnancy. Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands. Eur J Cancer. 2022 Aug;171:13-21. doi: 10.1016/j.ejca.2022.04.040. Epub 2022 Jun 10. PMID: 35696885.
 
166. Fastner G, Krug D, Meattini I, Gruber G, Poortmans P. Expert Discussion: Hypofractionated Radiation Therapy - Standard for All Indications? Breast Care (Basel). 2022 Apr;17(2):224-231. doi: 10.1159/000521552. Epub 2021 Dec 20. PMID: 35707177; PMCID: PMC9149542.
 
167. Aristei C, Bölükbaşı Y, Kaidar-Person O, Pfeffer R, Arenas M, Boersma LJ, Ciabattoni A, Coles CE, Franco P, Krengli M, Leonardi MC, Marazzi F, Masiello V, Meattini I, Montero A, Offersen B, Trigo ML, Bourgier C, Genovesi D, Kouloulias V, Morganti AG, Meduri B, Pasinetti N, Pedretti S, Perrucci E, Rivera S, Tombolini V, Vidali C, Valentini V, Poortmans P. Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. Crit Rev Oncol Hematol. 2022 Sep;177:103774. doi: 10.1016/j.critrevonc.2022.103774. Epub 2022 Jul 30. PMID: 35917884.
 
168. de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. PMID: 35952707.
 
169. Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, Hurkmans C, Høyer M, Langendijk JA, Kaidar-Person O, van der Linden Y, Meattini I, Niyazi M, Reynaert N, De Ruysscher D, Tanadini-Lang S, Hoskin P, Poortmans P, Nieder C. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022 Oct;23(10):e469-e478. doi: 10.1016/S1470-2045(22)00447-8. Erratum in: Lancet Oncol. 2022 Nov;23(11):e492. PMID: 36174633.
 
170. Meattini I, Palumbo I, Becherini C, Borghesi S, Cucciarelli F, Dicuonzo S, Fiorentino A, Spoto R, Poortmans P, Aristei C, Livi L. The Italian Association for Radiotherapy and Clinical Oncology (AIRO) position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation. Radiol Med. 2022 Dec;127(12):1407-1411. doi: 10.1007/s11547-022-01563-9. Epub 2022 Oct 6. PMID: 36201098; PMCID: PMC9747865.
 
171. Kaidar-Person O, Gentilini O, Poortmans P. Not only volumes matter for breast radiation therapy. Radiother Oncol. 2022 Dec;177:236-237. doi: 10.1016/j.radonc.2022.10.021. Epub 2022 Nov 2. PMID: 36334693.
 
172. Poortmans P, Kaidar-Person O, Meattini I. The Global Community Stands With American Society for Radiation Oncology's Experts in Protecting Women's Rights. Int J Radiat Oncol Biol Phys. 2022 Nov 18:S0360-3016(22)03526-X. doi: 10.1016/j.ijrobp.2022.11.013. Epub ahead of print. PMID: 36403687.
 
173. Franco P, De Felice F, Jagsi R, Nader Marta G, Kaidar-Person O, Gabrys D, Kim K, Ramiah D, Meattini I, Poortmans P. Breast cancer radiation therapy: A bibliometric analysis of the scientific literature. Clin Transl Radiat Oncol. 2022 Dec 5;39:100556. doi: 10.1016/j.ctro.2022.11.015. PMID: 36545362; PMCID: PMC9761378.
 
174. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. PMID: 36001857.
 
175. Le Guevelou J, Sargos P, Siva S, Ploussard G, Ost P, Gillessen S, Zilli T. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. Eur Urol Focus. 2022 Sep 20:S2405-4569(22)00205-X. doi: 10.1016/j.euf.2022.08.016. Epub ahead of print. PMID: 36151031.
 
176. Fonteyne V, Van Praet C, Ost P, Van Bruwaene S, Liefhooghe N, Berghen C, De Meerleer G, Vanneste B, Verbaeys C, Verbeke S, Lumen N. Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial. Eur Urol Focus. 2022 Sep 22:S2405-4569(22)00213-9. doi: 10.1016/j.euf.2022.09.005. Epub ahead of print. PMID: 36154809.
 
177. Ingrosso G, Bottero M, Becherini C, Caini S, Alì E, Lancia A, Ost P, Sanguineti G, Siva S, Zilli T, Francolini G, Bellavita R, Aristei C, Livi L, Detti B. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective. Semin Oncol. 2022 Oct;49(5):409-418. doi: 10.1053/j.seminoncol.2022.09.005. Epub 2022 Sep 24. PMID: 36192243.
 
178. Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, Ingrosso G, Alongi F, Aluwini S, Arcangeli S, Blanchard P, Conde Moreno A, Couñago F, Créhange G, Dirix P, Gomez Iturriaga A, Guckenberger M, Pasquier D, Sargos P, Scorsetti M, Supiot S, Tree AC, Zapatero A, Le Guevelou J, Ost P, Belka C. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022 Nov;176:199-207. doi: 10.1016/j.radonc.2022.10.005. Epub 2022 Oct 10. PMID: 36228761.
 
179. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, Tran PT, Berlin A. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It? Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):561-570. doi: 10.1016/j.ijrobp.2022.07.026. Epub 2022 Oct 13. PMID: 36244387.
 
180. Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, Tran PT. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. Eur Urol Oncol. 2022 Oct 22:S2588-9311(22)00171-7. doi: 10.1016/j.euo.2022.09.007. Epub ahead of print. PMID: 36283936.
 
181. Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, Yamoah K, Ost P. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2022 Nov 17:S0302-2838(22)02780-4. doi: 10.1016/j.eururo.2022.10.024. Epub ahead of print. PMID: 36404204.
 
182. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, Fendler WP. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023 Jan;20(1):23-47. doi: 10.1038/s41585-022-00670-6. Epub 2022 Dec 6. PMID: 36473945.
 
183. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Alicja Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022 Dec 6:S0302-2838(22)02789-0. doi: 10.1016/j.eururo.2022.11.002. Epub ahead of print. PMID: 36494221.
 
184. Bulens PP, Smets L, Debucquoy A, Joye I, D'Hoore A, Wolthuis A, Debrun L, Dekervel J, Van Cutsem E, Dresen R, Vandecaveye V, Deroose CM, Sagaert X, Haustermans K. Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study. Clin Transl Radiat Oncol. 2022 Jul 26;36:113-120. doi: 10.1016/j.ctro.2022.07.009. PMID: 35993092; PMCID: PMC9382364.
 
185. Baudelet M, Duprez F, Van den Steen L, Nuyts S, Nevens D, Goeleven A, Vandenbruaene C, Massonet H, Vergauwen A, Bollen H, Deschuymer S, Wouters K, Peeters M, Van Laer C, Mariën S, Van den Brekel M, van der Molen L, Vauterin T, van Dinther J, Verstraete H, Hutsebaut I, Meersschout S, Vanderveken O, De Bodt M, Van Nuffelen G; members of the Belgian PRESTO-group. Increasing Adherence to Prophylactic Swallowing Exercises During Head and Neck Radiotherapy: The Multicenter, Randomized Controlled PRESTO-Trial. Dysphagia. 2022 Sep 19:1–10. doi: 10.1007/s00455-022-10513-6. Epub ahead of print. PMID: 36121560; PMCID: PMC9484351.
 
186. Bossuyt E, Nevens D, Weytjens R, Taieb Mokaddem A, Verellen D. Assessing the impact of adaptations to the clinical workflow in radiotherapy using transit in vivo dosimetry. Phys Imaging Radiat Oncol. 2023 Jan 30;25:100420. doi: 10.1016/j.phro.2023.100420. PMID: 36820237; PMCID: PMC9937948.
 
187. Meduri B, Baldissera A, Iotti C, Scheijmans LJEE, Stam MR, Parisi S, Boersma LJ, Ammendolia I, Koiter E, Valli M, Scandolaro L, Busz D, Stenfert Kroese MC, Ciabatti S, Giacobazzi P, Ruggieri MP, Engelen A, Munafò T, Westenberg AH, Verhoeven K, Vicini R, D'Amico R, Lohr F, Bertoni F, Poortmans P, Frezza GP. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial. J Clin Oncol. 2023 Jan 9:JCO2201485. doi: 10.1200/JCO.22.01485. Epub ahead of print. PMID: 36623246.
 
188. Franco P, De Felice F, Kaidar-Person O, Gabrys D, Marta GN, Banini M, Livi L, Jagsi R, Coles CE, Poortmans P, Meattini I. Equity, diversity, and inclusion in radiation oncology: a bibliometric analysis and critical review. Int J Radiat Oncol Biol Phys. 2023 Feb 23:S0360-3016(23)00170-0. doi: 10.1016/j.ijrobp.2023.02.026. Epub ahead of print. PMID: 36841344.
 
189. Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. PMID: 36858728.
 
190. Siva S, Ost P, Ali M. The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy? JAMA Oncol. 2023 Jan 12. doi: 10.1001/jamaoncol.2022.6334. Epub ahead of print. PMID: 36633862.
 
191. Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, Tran PT. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 26:S0360-3016(22)03628-8. doi: 10.1016/j.ijrobp.2022.12.006. Epub ahead of print. PMID: 36708787.
 
192. Juul SJ, Kicinski M, Schaapveld M, Rossetti S, Aleman BMP, Liu L, van Leeuwen FE, Meijnders P, Krol ADG, Janus CPM, Hutchings M, Maraldo MV. Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC-Dutch late effects cohort-linked data. Eur J Haematol. 2023 Mar;110(3):243-252. doi: 10.1111/ejh.13899. Epub 2022 Nov 25. PMID: 36369842.
 
193. Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials. J Cancer Surviv. 2022 Nov 28. doi: 10.1007/s11764-022-01305-w. Epub ahead of print. PMID: 36441393.
 
194. Bultijnck R, Rammant E, Raes A, Vandecasteele N, Decaestecker K, Fonteyne V, Lumen N, Ost P, Deforche B. Experiences of Men With Prostate Cancer Participating in a Clinical Pathway With a Supervised Group-based Exercise Program to Combat Androgen Deprivation-Induced Side Effects: A Qualitative Focus Group Study. Semin Oncol Nurs. 2023 Jun;39(3):151404. doi: 10.1016/j.soncn.2023.151404. Epub 2023 Mar 15. PMID: 36925317.
 
195. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.
 
196. Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, Rans K, Liefhooghe N, Wallaert S, Paelinck L. Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154088. doi: 10.1177/15330338231154088. PMID: 37016933; PMCID: PMC10084583.
 
197. Saesen R, Van Hemelrijck M, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, Eisenhauer EA, Freitas A, Gronchi A, Hernán MA, Hulstaert F, Ost P, Szturz P, Verkooijen HM, Weller M, Wilson R, Lacombe D, van der Graaf WT. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2023 Jun;186:52-61. doi: 10.1016/j.ejca.2023.03.013. Epub 2023 Mar 21. PMID: 37030077.
 
198. Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol. 2023 Jul;34(7):605-614. doi: 10.1016/j.annonc.2023.04.515. Epub 2023 May 8. PMID: 37164128; PMCID: PMC10330666.
 
199. Danckaert W, Ost P, De Wagter C. Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy. J Appl Clin Med Phys. 2023 Aug;24(8):e14003. doi: 10.1002/acm2.14003. Epub 2023 May 11. PMID: 37170654; PMCID: PMC10402685.
 
200. Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, Tran PT. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol. 2023 May 10:S0302-2838(23)02790-2. doi: 10.1016/j.eururo.2023.04.025. Epub ahead of print. PMID: 37173210.
 
201. Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.05.005. Epub ahead of print. PMID: 37217391.
 
202. Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, Üstmert S, Lavent F, Beels L, Grönberg H, Ost P, Lindberg J, De Laere B. AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Open Sci. 2023 May 30;53:63-66. doi: 10.1016/j.euros.2023.05.008. PMID: 37292496; PMCID: PMC10244905.
 
203. Pizurica M, Larmuseau M, Van der Eecken K, de Schaetzen van Brienen L, Carrillo-Perez F, Isphording S, Lumen N, Van Dorpe J, Ost P, Verbeke S, Gevaert O, Marchal K. Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer. Cancer Res. 2023 Sep 1;83(17):2970-2984. doi: 10.1158/0008-5472.CAN-22-3113. PMID: 37352385.
 
204. Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, Lievens Y, Surmont V, Brochez L, Reynders D, Danckaert W, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Ost P. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Jul 6:e232132. doi: 10.1001/jamaoncol.2023.2132. Epub ahead of print. PMID: 37410476; PMCID: PMC10326732.
 
205. Sanmamed N, Gómez-Rivas J, Buchser D, Montijano M, Gómez-Aparicio MA, Duque-Santana V, Torres L, Zilli T, Ost P, López-Campos F, Couñago F. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd? Clin Genitourin Cancer. 2023 Aug 7:S1558-7673(23)00185-4. doi: 10.1016/j.clgc.2023.08.002. Epub ahead of print. PMID: 37599133.
 
206. Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials. Acta Oncol. 2023 Jul;62(7):744-752. doi: 10.1080/0284186X.2023.2195561. Epub 2023 Apr 11. PMID: 37039661.
 
207. Fiagan YAC, Bossuyt E, Nevens D, Machiels M, Chiairi I, Joye I, Meijnders P, Gevaert T, Verellen D. The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy. Radiother Oncol. 2023 Jul;184:109676. doi: 10.1016/j.radonc.2023.109676. Epub 2023 Apr 20. PMID: 37084887.
 
208. Aleman BMP, Ricardi U, van der Maazen RWM, Meijnders P, Beijert M, Boros A, Izar F, Janus CPM, Levis M, Martin V, Specht L, Corning C, Clementel E, Raemaekers JM, André MP, Federico M, Fortpied C, Girinsky T. A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned. Int J Radiat Oncol Biol Phys. 2023 May 12:S0360-3016(23)00455-8. doi: 10.1016/j.ijrobp.2023.05.011. Epub ahead of print. PMID: 37179034.
 
209. Baudelet M, Van den Steen L, Duprez F, Goeleven A, Nuyts S, Nevens D, Vandenbruaene C, Massonet H, Vergauwen A, Vauterin T, Verstraete H, Wouters K, Vanderveken O, De Bodt M, Van Nuffelen G; members of the Belgian PRESTO-group. Prophylactic Swallowing Therapy During Head-and-Neck Cancer Radiotherapy: Effect of Service-Delivery Mode and Overall Adherence Level on Swallowing Function and Muscle Strength-the PRESTO Trial. Dysphagia. 2023 Aug 8. doi: 10.1007/s00455-023-10609-7. Epub ahead of print. PMID: 37550571.
 
210. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R, Lindberg K. Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors. Int J Radiat Oncol Biol Phys. 2023 Jul 8:S0360-3016(23)04478-4. doi: 10.1016/j.ijrobp.2023.06.246. Epub ahead of print. PMID: 37423292.
 
211. Machiels M, Oulkadi R, Tramm T, Stecklein SR, Somaiah N, De Caluwé A, Klein J, Tran WT, Salgado R. Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers. Breast. 2023 Jul 1;71:13-21. doi: 10.1016/j.breast.2023.06.010. Epub ahead of print. PMID: 37437386.
 
212. Saifi O, Bachir B, Panoff J, Poortmans P, Zeidan YH. Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. Radiother Oncol. 2023 Jul;184:109668. doi: 10.1016/j.radonc.2023.109668. Epub 2023 Apr 6. PMID: 37030399.
 
213. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. PMID: 37061269.
 
214. Weber WP, Davide Gentilini O, Morrow M, Montagna G, de Boniface J, Fitzal F, Wyld L, Rubio IT, Matrai Z, King TA, Saccilotto R, Galimberti V, Maggi N, Andreozzi M, Sacchini V, Castrezana López L, Loesch J, Schwab FD, Eller R, Heidinger M, Haug M, Kurzeder C, Di Micco R, Banys-Paluchowski M, Ditsch N, Harder Y, Paulinelli RR, Urban C, Benson J, Bjelic-Radisic V, Potter S, Knauer M, Thill M, Vrancken Peeters MJ, Kuemmel S, Heil J, Gulluoglu BM, Tausch C, Ganz-Blaettler U, Shaw J, Dubsky P, Poortmans P, Kaidar-Person O, Kühn T, Gnant M. Uncertainties and controversies in axillary management of patients with breast cancer. Cancer Treat Rev. 2023 Jun;117:102556. doi: 10.1016/j.ctrv.2023.102556. Epub 2023 Apr 23. PMID: 37126938.
 
215. Kaidar-Person O, Giasafaki P, Boersma L, De Brouwer P, Weltens C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Bartelink H, Struikmans H, Fortpied C, Poortmans PM; EORTC Radiation Oncology and Breast Cancer Groups. Mapping the location of local and regional recurrences according to breast cancer surgery and radiation therapy: Results from EORTC 22922/10925. Radiother Oncol. 2023 Aug;185:109698. doi: 10.1016/j.radonc.2023.109698. Epub 2023 May 23. PMID: 37211281.
 
216. Aristei C, Kaidar-Person O, Boersma L, Leonardi MC, Offersen B, Franco P, Arenas M, Bourgier C, Pfeffer R, Kouloulias V, Bölükbaşı Y, Meattini I, Coles C, Luis AM, Masiello V, Palumbo I, Morganti AG, Perrucci E, Tombolini V, Krengli M, Marazzi F, Trigo L, Borghesi S, Ciabattoni A, Ratoša I, Valentini V, Poortmans P. The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Crit Rev Oncol Hematol. 2023 Jul;187:104035. doi: 10.1016/j.critrevonc.2023.104035. Epub 2023 May 26. PMID: 37244324.
 
217. McDonald F, Belka C, Hurkmans C, Jereczek-Fossa BA, Poortmans P, van de Kamer JB, Azizaj E, Franco P. Introducing the ESTRO Guidelines Committee, the driving force for the new generation of ESTRO guidelines. Radiother Oncol. 2023 Aug;185:109724. doi: 10.1016/j.radonc.2023.109724. Epub 2023 May 25. PMID: 37244357.
 
218. McDonald F, Belka C, Hurkmans C, Jereczek-Fossa BA, Poortmans P, van de Kamer JB, Azizaj E, Franco P. Introducing the ESTRO Guidelines Committee, the driving force for the new generation of ESTRO guidelines. Radiother Oncol. 2023 Aug;185:109724. doi: 10.1016/j.radonc.2023.109724. Epub 2023 May 25. PMID: 37244357.
 
219. Kastora SL, Holmquist A, Valachis A, Rocco N, Meattini I, Somaiah N, Peled A, Chatterjee A, Catanuto G, Tasoulis MK, Nava MB, Poortmans P, Pusic A, Masannat Y, Karakatsanis A. Outcomes of Different Quality of Life Assessment Modalities After Breast Cancer Therapy: A Network Meta-analysis. JAMA Netw Open. 2023 Jun 1;6(6):e2316878. doi: 10.1001/jamanetworkopen.2023.16878. PMID: 37279001; PMCID: PMC10245190.
 
220. Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2023 Sep;119:102586. doi: 10.1016/j.ctrv.2023.102586. Epub 2023 Jun 15. PMID: 37336117.
 
221. Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, Becherini C, Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J, Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2023 Sep;186:109805. doi: 10.1016/j.radonc.2023.109805. Epub 2023 Jul 10. PMID: 37437610.
 
222. Oladeru OT, Dunn SA, Li J, Coles CE, Yamauchi C, Chang JS, Cheng SH, Kaidar-Person O, Meattini I, Ramiah D, Kirby A, Hijal T, Marta GN, Poortmans P, Isern-Verdum J, Zissiadis Y, Offersen BV, Refaat T, Elsayad K, Hijazi H, Dengina N, Belkacemi Y, Luo FD, Lu S, Griffin C, Collins M, Ryan P, Larios D, Warren LE, Punglia RS, Wong JS, Spiegel DY, Jagsi R, Taghian A, Bellon JR, Ho AY. Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic. JCO Glob Oncol. 2023 Jul;9:e2300010. doi: 10.1200/GO.23.00010. PMID: 37471670.
 
223. Blommaert J, De Saint-Hubert M, Depuydt T, Oldehinkel E, Poortmans P, Amant F, Lambrecht M. Challenges and opportunities for proton therapy during pregnancy. Acta Obstet Gynecol Scand. 2023 Jul 25. doi: 10.1111/aogs.14645. Epub ahead of print. PMID: 37491770.
 
224. Kaidar-Person O, Pfob A, Gentilini OD, Borisch B, Bosch A, Cardoso MJ, Curigliano G, De Boniface J, Denkert C, Hauser N, Heil J, Knauer M, Kühn T, Lee HB, Loibl S, Mannhart M, Meattini I, Montagna G, Pinker K, Poulakaki F, Rubio IT, Sager P, Steyerova P, Tausch C, Tramm T, Vrancken Peeters MJ, Wyld L, Yu JH, Weber WP, Poortmans P, Dubsky P. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. EClinicalMedicine. 2023 Jul 14;61:102085. doi: 10.1016/j.eclinm.2023.102085. PMID: 37528842; PMCID: PMC10388578.
 
225. Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. Lancet Oncol. 2023 Aug;24(8):e331-e343. doi: 10.1016/S1470-2045(23)00286-3. PMID: 37541279.
 
226. Loibl S, Azim HA Jr, Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ, Hoeltzenbein M, Johansson ALV, Maggen C, Markert UR, Peccatori F, Poortmans P, Saloustros E, Saura C, Schmid P, Stamatakis E, van den Heuvel-Eibrink M, van Gerwen M, Vandecaveye V, Pentheroudakis G, Curigliano G, Amant F. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.08.001. Epub ahead of print. PMID: 37572987.
 
227. Bozzao A, Weber D, Crompton S, Braz G, Csaba D, Dhermain F, Finocchiaro G, Flannery T, Kramm C, Law I, Marucci G, Oliver K, Ostgathe C, Paterra R, Pesce G, Smits M, Soffietti R, Terkola R, Watts C, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care: adult glioma. J Cancer Policy. 2023 Aug 25:100438. doi: 10.1016/j.jcpo.2023.100438. Epub ahead of print. PMID: 37634617.
 
228. Le Guevelou J, Magne N, Counago F, Magsanoc JM, Vermeille M, De Crevoisier R, Benziane-Ouaritini N, Ost P, Niazi T, Supiot S, Sargos P. Stereotactic body radiation therapy after radical prostatectomy: current status and future directions. World J Urol. 2023 Nov;41(11):3333-3344. doi: 10.1007/s00345-023-04605-7. Epub 2023 Sep 19. PMID: 37725131.
 
229. De Kerf G, Claessens M, Raouassi F, Mercier C, Stas D, Ost P, Dirix P, Verellen D. A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer. Phys Imaging Radiat Oncol. 2023 Sep 23;28:100494. doi: 10.1016/j.phro.2023.100494. PMID: 37809056; PMCID: PMC10550805.
 
230. Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, Shetty AC, Chowdhury DD, Chan A, Carrieri FA, Hathout L, Ennis R, Jabbour SK, Parikh R, Molitoris J, Song DY, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Lafargue A, Van Der Eecken K, Bunz F, Ost P, Tran PT, Deek MP. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. Prostate. 2024 Jan;84(1):87-99. doi: 10.1002/pros.24629. Epub 2023 Oct 9. PMID: 37812042. IF 2.6
 
231. Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, Zilli T. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. 2024 Jun;7(3):462-468. doi: 10.1016/j.euo.2023.09.007. Epub 2023 Oct 9. PMID: 37821242. IF 8.3
 
232. Danckaert W, Spaas M, Sundahl N, De Bruycker A, Fonteyne V, De Paepe E, De Wagter C, Vanhaecke L, Ost P. Microbiome and metabolome dynamics during radiotherapy for prostate cancer. Radiother Oncol. 2023 Dec;189:109950. doi: 10.1016/j.radonc.2023.109950. Epub 2023 Oct 10. PMID: 37827280.
 
233. Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, Kawada T, von Deimling M, Pradere B, Rivas JG, Gandaglia G, van den Bergh RCN, Goldner G, Supiot S, Zilli T, Trinh QD, Nguyen PL, Briganti A, Ost P, Ploussard G, Shariat SF. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. 2024 Feb;85(2):125-138. doi: 10.1016/j.eururo.2023.10.012. Epub 2023 Nov 7. PMID: 37945451. IF 25.3
 
234. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X; Biobank Japan Project; Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJF, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden SK, Easton DF, Ambs S, Edwards TL, Mägi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9. PMID: 37945903; PMCID: PMC10841479.
 
235. Lorton O, Achard V, Koutsouvelis N, Jaccard M, Vanhoutte F, Dipasquale G, Ost P, Zilli T. Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial. Adv Radiat Oncol. 2023 Jun 13;8(6):101290. doi: 10.1016/j.adro.2023.101290. PMID: 38047214; PMCID: PMC10692293.
 
236. Mercier C, Billiet C, Ost P, Joye I, Meijnders P, Vermeulen P, Dirix L, Verellen D, Dirix P. Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1490-1496. doi: 10.1016/j.ijrobp.2023.12.021. Epub 2023 Dec 25. PMID: 38151189. IF 6.4
 
237. Warner EW, Van der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Schönlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerkhove G, Ost P, Wyatt AW. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat Cancer. 2024 Jan;5(1):114-130. doi: 10.1038/s43018-023-00692-y. Epub 2024 Jan 4. PMID: 38177459. IF 23.5
 
238. Peters C, Vandewiele J, Lievens Y, van Eijkeren M, Fonteyne V, Boterberg T, Deseyne P, Veldeman L, De Neve W, Monten C, Braems S, Duprez F, Vandecasteele K, Ost P. Incidence and radiotherapy treatment patterns of complicated bone metastases. J Bone Oncol. 2023 Dec 23;44:100519. doi: 10.1016/j.jbo.2023.100519. PMID: 38179260; PMCID: PMC10765249.
 
239. Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol. 2024 Jan 24:S2588-9311(24)00034-8. doi: 10.1016/j.euo.2024.01.009. Epub ahead of print. PMID: 38272747. IF 8.3
 
240. Bultijnck R, Van Hemelrijck M, Fonteyne V, Livi L, Jereczek-Fossa BA, Hemmatazad H, Mayinger M, Peulen H, Verbeke L, Ramella S, Castro P, Tsoutsou P, Stellamans K, Shaukat A, Orazem M, Jeene P, Braam P, Verkooijen H, Simek IM, Alongi F, Clementel E, Fortpied C, Machingura A, Boakye Oppong F, Guckenberger M, Ost P. Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort. Clin Transl Radiat Oncol. 2023 Dec 29;45:100715. doi: 10.1016/j.ctro.2023.100715. PMID: 38274388; PMCID: PMC10808936.
 
241. Fonteyne V, Berghen C, Van Praet C, Vanderstraeten B, Verbeke S, Villeirs G, Colman R, Vanneste B, Ost P, De Meerleer G, Lumen N. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial. Radiother Oncol. 2024 Apr;193:110089. doi: 10.1016/j.radonc.2024.110089. Epub 2024 Jan 24. PMID: 38278333. IF 4.9
 
242. Bindels BJJ, Mercier C, Gal R, Verlaan JJ, Verhoeff JJC, Dirix P, Ost P, Kasperts N, van der Linden YM, Verkooijen HM, van der Velden JM. Stereotactic Body and Conventional Radiotherapy for Painful Bone Metastases: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2355409. doi: 10.1001/jamanetworkopen.2023.55409. PMID: 38345820; PMCID: PMC10862159. IF 10.5
 
243. Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiother Oncol. 2024 Jun;195:110235. doi: 10.1016/j.radonc.2024.110235. Epub 2024 Mar 19. PMID: 38508239. IF 4.9
 
244. Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, Chang D, Dirix P, Armstrong AJ, Campbell B, Lopez Campos F, Berenguer M, Ramotar M, Conde-Moreno A, Berlin A, Bosetti DG, Corcoran N, Koontz B, Mercier C, Siva S, Pryor D, Ost P, Huynh MA, Kroeze S, Stish B, Kiess A, Trock B, Tran PT, Gillessen S, Sweeney C. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Apr 2:S2588-9311(24)00086-5. doi: 10.1016/j.euo.2024.03.010. Epub ahead of print. PMID: 38570239. IF 8.3
 
245. Ost P, Siva S, Zilli T. OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full? Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.03.039. Epub ahead of print. PMID: 38679526. IF 25.3
 
246. Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJM, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LGW, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. Lancet Oncol. 2024 May;25(5):e193-e204. doi: 10.1016/S1470-2045(24)00023-8. PMID: 38697165. IF 41.6
 
247. Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar P. Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial. Clin Transl Radiat Oncol. 2024 Apr 25;47:100786. doi: 10.1016/j.ctro.2024.100786. PMID: 38706726; PMCID: PMC11067361. IF 2.7
 
248. Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, Cao Y, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Kiess A, Song DY, DeWeese T, Pienta KJ, Barbieri C, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Tran PT, Ost P, Deek MP. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Jun 10:S2588-9311(24)00142-1. doi: 10.1016/j.euo.2024.05.011. Epub ahead of print. PMID: 38862340. IF 8.3
 
249. Alongi F, Nicosia L, Ricardi U, Scorsetti M, Greto D, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Simek IM, Peulen H, Dirix P, Verbeke L, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Fortpied C, Boakye Oppong F, Ost P, Guckenberger M. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort. Radiother Oncol. 2024 Jul 31;199:110466. doi: 10.1016/j.radonc.2024.110466. Epub ahead of print. PMID: 39094630. IF 4.9
 
250. De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergström R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjälm-Eriksson M, Pettersson L, Ullén A, Lumen N, Enblad G, Thellenberg Karlsson C, Jänes E, Sandzén J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Grönberg H, Lindberg J. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03204-2. Epub ahead of print. PMID: 39164518. IF 58.7
 
251. Dal Pra A, Dirix P, Khoo V, Carrie C, Cozzarini C, Fonteyne V, Ghadjar P, Gomez-Iturriaga A, Panebianco V, Zapatero A, Bossi A, Wiegel T. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clin Transl Radiat Oncol. 2023 May 9;41:100638. doi: 10.1016/j.ctro.2023.100638. PMID: 37251620; PMCID: PMC10209331.
 
252. Dirix P, Dal Pra A, Khoo V, Carrie C, Cozzarini C, Fonteyne V, Ghadjar P, Gomez-Iturriaga A, Schmidt-Hegemann NS, Panebianco V, Zapatero A, Bossi A, Wiegel T. ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy. Clin Transl Radiat Oncol. 2023 Sep 23;43:100684. doi: 10.1016/j.ctro.2023.100684. PMID: 37808453; PMCID: PMC10556584.
 
253. Achard V, Fournier B, D'Haese D, Krzystyniak J, Tombal B, Roupret M, Sargos P, Dirix P. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial. Eur Urol Oncol. 2024 Mar 30:S2588-9311(24)00084-1. doi: 10.1016/j.euo.2024.03.008. Epub ahead of print. PMID: 38556413. IF 8.3
 
254. Van den Brande R, Thijs D, Bilsky M, Peeters M, Billiet C, Van de Kelft E. Treatment of ambulatory patients with metastatic epidural spinal cord compression: a systematic review and meta-analysis. J Neurosurg Spine. 2023 Oct 27;40(2):175-184. doi: 10.3171/2023.8.SPINE23541. PMID: 37890190.
 
255. Guckenberger M, Billiet C, Schnell D, Franzese C, Spałek M, Rogers S, Stelmes JJ, Aebersold DM, Hemmatazad H, Zimmermann F, Zimmer J, Zilli T, Bruni A, Baumert BG, Nägler F, Gut P, Förster R, Madani I. Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. Cancer. 2024 Aug 1;130(15):2713-2722. doi: 10.1002/cncr.35310. Epub 2024 Apr 6. PMID: 38581694. IF 6.1
 
256. Van den Brande R, Van den Kieboom M, Peeters M, Billiet C, Van de Kelft E. Remineralization of lytic spinal metastases after radiation therapy - A retrospective cohort study comparing conventional external beam radiation therapy with stereotactic ablative body radiation. Clin Transl Radiat Oncol. 2024 Jun 13;48:100805. doi: 10.1016/j.ctro.2024.100805. PMID: 38988807; PMCID: PMC11231653. IF 2.7
 
257. Vanreusel V, Gasparini A, Galante F, Mariani G, Pacitti M, Colijn A, Reniers B, Yalvac B, Vandenbroucke D, Peeters M, Leblans P, Felici G, Verellen D, de Freitas Nascimento L. Optically stimulated luminescence system as an alternative for radiochromic film for 2D reference dosimetry in UHDR electron beams. Phys Med. 2023 Oct;114:103147. doi: 10.1016/j.ejmp.2023.103147. Epub 2023 Oct 5. PMID: 37804712.
 
258. Claessens M, De Kerf G, Vanreusel V, Mollaert I, Hernandez V, Saez J, Jornet N, Verellen D. Multi-institutional generalizability of a plan complexity machine learning model for predicting pre-treatment quality assurance results in radiotherapy. Phys Imaging Radiat Oncol. 2023 Dec 19;29:100525. doi: 10.1016/j.phro.2023.100525. PMID: 38204910; PMCID: PMC10776441.
 
259. Claessens M, Vanreusel V, Gasparini A, Nascimento LF, Yalvec B, Reniers B, Verellen D. Automated determination of the ion-recombination correction factor (ksat) in ultra-high dose rate electron radiation therapy. Med Phys. 2024 Jun;51(6):4536-4545. doi: 10.1002/mp.17085. Epub 2024 Apr 19. PMID: 38639653. IF 3.2
 
260. Kirby AM, Guckenberger M, Slotman BJ, Clark CH, Eriksen JG, van der Heide U, De Ioanna S, Gasparotto C, Cortese AJ; ESTRO Board of Directors. European Society of Radiotherapy and Oncology (ESTRO) strategy 2024-2026: Growth and diversification in a rapidly changing world. Radiother Oncol. 2024 Jul;196:110283. doi: 10.1016/j.radonc.2024.110283. Epub 2024 Apr 18. PMID: 38641262. IF 4.9
 
261. Garibaldi C, Beddar S, Bizzocchi N, Tobias Böhlen T, Iliaskou C, Moeckli R, Psoroulas S, Subiel A, Taylor PA, Van den Heuvel F, Vanreusel V, Verellen D. Minimum and optimal requirements for a safe clinical implementation of ultra-high dose rate radiotherapy: A focus on patient's safety and radiation protection. Radiother Oncol. 2024 Jul;196:110291. doi: 10.1016/j.radonc.2024.110291. Epub 2024 Apr 20. PMID: 38648991. IF 4.9
 
262. Lievens Y, Janssens S, Lambrecht M, Engels H, Geets X, Jansen N, Moretti L, Remouchamps V, Roosens S, Stellamans K, Verellen D, Weltens C, Weytjens R, Van Damme N; Belgian College for Physicians of Radiation Oncology Centres. Coverage with evidence development program on stereotactic body radiotherapy in Belgium (2013-2019): a nationwide registry-based prospective study. Lancet Reg Health Eur. 2024 Jul 6;44:100992. doi: 10.1016/j.lanepe.2024.100992. PMID: 39045286; PMCID: PMC11265534. IF 13.6
 
263. Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B; St Gallen Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023 Nov;34(11):970-986. doi: 10.1016/j.annonc.2023.08.017. Epub 2023 Sep 6. PMID: 37683978.
 
264. Kaidar-Person O, Offersen BV, Tramm T, Christiansen P, Damsgaard TE, Kothari A, Poortmans P. The King is in the altogether: Radiation therapy after oncoplastic breast surgery. Breast. 2023 Dec;72:103584. doi: 10.1016/j.breast.2023.103584. Epub 2023 Sep 25. PMID: 37783134; PMCID: PMC10562190.
 
265. Willmann J, Appelt AL, Balermpas P, Baumert BG, de Ruysscher D, Hoyer M, Hurkmans C, Kaidar-Person O, Meattini I, Niyazi M, Poortmans P, Reynaert N, Tandini-Lang S, van der Linden Y, Nieder C, Andratschke N. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiother Oncol. 2023 Dec;189:109947. doi: 10.1016/j.radonc.2023.109947. Epub 2023 Oct 6. PMID: 37806559.
 
266. Kaidar-Person O, Tramm T, Kuehn T, Gentilini O, Prat A, Montay-Gruel P, Meattini I, Poortmans P. Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future. Radiol Med. 2024 Feb;129(2):315-327. doi: 10.1007/s11547-023-01743-1. Epub 2023 Nov 3. PMID: 37922004. IF 9.7
 
267. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 Nov 25;402(10416):1991-2003. doi: 10.1016/S0140-6736(23)01082-6. Epub 2023 Nov 3. PMID: 37931633.
 
268. De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta GN, Denis Z, Drisis S, Vandekerkhove C, Desmet A, Philippson C, Craciun L, Veys I, Larsimont D, Paesmans M, Van Gestel D, Salgado R, Sotiriou C, Piccart-Gebhart M, Ignatiadis M, Buisseret L. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial. J Immunother Cancer. 2023 Dec 6;11(12):e007279. doi: 10.1136/jitc-2023-007279. PMID: 38056900; PMCID: PMC10711977.
 
269. Meattini I, Marta GN, Carroll S, Rivera S, Lamoury G, De Felice F, Lambertini M, Livi L, Kaidar-Person O, Poortmans P. Omission of radiation therapy after breast-conserving surgery for biologically favourable tumours in younger patients: The wrong answer to the right question. Radiother Oncol. 2024 Jan;190:110045. doi: 10.1016/j.radonc.2023.110045. Epub 2023 Dec 6. PMID: 38065440. IF 4.9
 
270. Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. PMID: 38101773. IF 56.7
 
271. Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2024 Jun;195:110060. doi: 10.1016/j.radonc.2023.110060. Epub 2023 Dec 19. PMID: 38122852. IF 4.9
 
272. Wintraecken VM, Boersma LJ, van Roozendaal LM, de Vries J, van Kuijk SMJ, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, van de Vijver KKBT, Westenberg AH, de Wilt JHW, Smidt ML, Simons JM; BOOG 2013-08 group. Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial. Radiother Oncol. 2024 Feb;191:110069. doi: 10.1016/j.radonc.2023.110069. Epub 2023 Dec 21. PMID: 38141879. IF 4.9
 
273. Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. PMID: 38301705. IF 41.6
 
274. Wong HCY, Wallen MP, Chan AW, Dick N, Bonomo P, Bareham M, Wolf JR, van den Hurk C, Fitch M, Chow E, Chan RJ; MASCC BCRAL Expert Panel and the Oncodermatology and Survivorship Study Groups. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations. EClinicalMedicine. 2024 Feb 2;68:102441. doi: 10.1016/j.eclinm.2024.102441. PMID: 38333542; PMCID: PMC10850412. IF 9.6
 
275. Gentilini OD, Cardoso MJ, Senkus E, Poortmans P. De-escalation of loco-regional treatments: Time to find a balance. Breast. 2024 Feb;73:103673. doi: 10.1016/j.breast.2024.103673. Epub 2024 Jan 16. PMID: 38295751; PMCID: PMC10844673. IF 5.7
 
276. Cardoso MJ, Poortmans P, Senkus E, Gentilini OD, Houssami N. Breast cancer highlights from 2023: Knowledge to guide practice and future research. Breast. 2024 Apr;74:103674. doi: 10.1016/j.breast.2024.103674. Epub 2024 Jan 27. PMID: 38340683; PMCID: PMC10869942. IF 5.7
 
277. Chirilă ME, Kraja F, Marta GN, Neves Junior WFP, de Arruda GV, Gouveia AG, Franco P, Poortmans P, Ratosa I. Organ-sparing techniques and dose-volume constrains used in breast cancer radiation therapy - Results from European and Latin American surveys. Clin Transl Radiat Oncol. 2024 Feb 19;46:100752. doi: 10.1016/j.ctro.2024.100752. PMID: 38425691; PMCID: PMC10900109. IF 2.7
 
278. Cardoso MJ, de Boniface J, Dodwell D, Kaidar-Person O, Poortmans P, van Maaren MC. Which real indications remain for mastectomy? Lancet Reg Health Am. 2024 Apr 4;33:100734. doi: 10.1016/j.lana.2024.100734. PMID: 38590325; PMCID: PMC11000187. IF 7.0
 
279. de Wild SR, van Roozendaal LM, de Wilt JHW, van Dalen T, van der Hage JA, van Duijnhoven FH, Simons JM, Schipper RJ, de Munck L, van Kuijk SMJ, Boersma LJ, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, van de Vijver KKBT, de Vries J, Westenberg AH, Strobbe LJA, Smidt ML. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). Br J Surg. 2024 Apr 3;111(4):znae077. doi: 10.1093/bjs/znae077. PMID: 38597154; PMCID: PMC11004788. IF 8.6
 
280. Struikmans H, Petoukhova A, Schreur JHM, Mast ME, Poortmans PM. Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose? Acta Oncol. 2024 Apr 10;63:175-178. doi: 10.2340/1651-226X.2024.34751. PMID: 38597665; PMCID: PMC11332529. IF 3.1
 
281. Franciosini G, Carlotti D, Cattani F, De Gregorio A, De Liso V, De Rosa F, Di Francesco M, Di Martino F, Felici G, Pensavalle JH, Leonardi MC, Marafini M, Muscato A, Paiar F, Patera V, Poortmans P, Sciubba A, Schiavi A, Toppi M, Traini G, Trigilio A, Sarti A. IOeRT conventional and FLASH treatment planning system implementation exploiting fast GPU Monte Carlo: The case of breast cancer. Phys Med. 2024 May;121:103346. doi: 10.1016/j.ejmp.2024.103346. Epub 2024 Apr 11. PMID: 38608421. IF 3.2
 
282. Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C; Lancet Breast Cancer Commission. The Lancet Breast Cancer Commission. Lancet. 2024 May 11;403(10439):1895-1950. doi: 10.1016/S0140-6736(24)00747-5. Epub 2024 Apr 15. PMID: 38636533. IF 98.4
 
283. Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, Graff SL, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2701-2705. doi: 10.1007/s00259-024-06694-x. PMID: 38693453. IF 8.6
 
284. Mitrea DA, Froicu EM, Prenen H, Gambacorta MA, Span PN, Poortmans P. Combining immunotherapy and radiation therapy in gastrointestinal cancers: A review. Crit Rev Oncol Hematol. 2024 Jul;199:104381. doi: 10.1016/j.critrevonc.2024.104381. Epub 2024 May 11. PMID: 38735504. IF 5.5
 
285. Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, Graff SL, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2706-2732. doi: 10.1007/s00259-024-06696-9. Epub 2024 May 14. PMID: 38740576; PMCID: PMC11224102. IF 8.6
 
286. Aristei C, Camilli F, Epifani V, Borghesi S, Palumbo I, Bini V, Poortmans P. A systematic review and meta-analysis of intraoperative electron radiation therapy delivered with a dedicated mobile linac for partial breast irradiation in early breast cancer. Breast. 2024 Aug;76:103759. doi: 10.1016/j.breast.2024.103759. Epub 2024 Jun 4. PMID: 38851057; PMCID: PMC11219955. IF 5.7
 
287. Kaidar-Person O, Faermann R, Polikar D, Cohen K, Bernstein-Molho R, Morrow M, Boersma LJ, Offersen BV, Poortmans P, Sklair-Levy M, Anaby D. A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction. Breast Cancer Res Treat. 2024 Jul 9. doi: 10.1007/s10549-024-07425-4. Epub ahead of print. PMID: 38980506. IF 3.0
 
288. Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389. Epub ahead of print. PMID: 38985794. IF 6.1
 
289. Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, Freres P, Hirte H, Seidel C, Walenkamp A, Lukacova S, Meijnders P, Blais A, Ducray F, Verschaeve V, Nicholas G, Balana C, Bota DA, Preusser M, Nuyens S, Dhermain F, van den Bent M, O'Callaghan CJ, Vanlancker M, Mason W, Weller M; EORTC Brain Tumor Group and the Canadian Cancer Trials Group. Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial. Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093/neuonc/noae053. Epub ahead of print. PMID: 38502052. IF 16.4
 
290. Rossetti S, Juul SJ, van der Kaaij MAE, Fortpied C, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, Plattel WJ, Hutchings M, Maraldo MV. Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials. Leuk Lymphoma. 2024 Aug 12:1-5. doi: 10.1080/10428194.2024.2390565. Epub ahead of print. PMID: 39133256. IF 2.2
 
291. Baudelet M, Van den Steen L, Duprez F, Goeleven A, Nuyts S, Nevens D, Vandenbruaene C, Massonet H, Vergauwen A, Vauterin T, Verstraete H, Wouters K, Vanderveken O, De Bodt M, Van Nuffelen G; members of the Belgian PRESTO-group. Prophylactic Swallowing Therapy During Head-and-Neck Cancer Radiotherapy: Effect of Service-Delivery Mode and Overall Adherence Level on Swallowing Function and Muscle Strength-the PRESTO Trial. Dysphagia. 2024 Apr;39(2):267-281. doi: 10.1007/s00455-023-10609-7. Epub 2023 Aug 8. PMID: 37550571; PMCID: PMC10957706. IF 2.2
 
292. Petit SF, Portik D, Abravan A, Bertholet J, Callens D, Dubois L, Franco P, Horsholt Kristensen M, Montay-Gruel P, Nevens D, Perryck S, Røe Redalen K, Tomasik B, Webster A, Grau Eriksen J, Heukelom J. Professional development through mentoring: Final evaluation of the pilot mentoring programme of the European society of radiotherapy and oncology. Radiother Oncol. 2024 Jun;195:110226. doi: 10.1016/j.radonc.2024.110226. Epub 2024 Mar 15. PMID: 38492670. IF 4.9
 
293. Zilli T, Ost P. Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007. Eur Urol Oncol. 2024 Oct;7(5):1152-1153. doi: 10.1016/j.euo.2024.02.002. Epub 2024 Feb 28. PMID: 38418267.
 
294. Ost P, Mottet N. PSMA PET-CT, When Seeing Becomes Improving. Int J Radiat Oncol Biol Phys. 2024 Nov 1;120(3):646-647. doi: 10.1016/j.ijrobp.2023.12.030. Epub 2024 Sep 24. PMID: 39326951.
 
295. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11. PMID: 39394013.
 
296. Wang JH, Deek MP, Mendes AA, Song Y, Shetty A, Bazyar S, Van der Eecken K, Chen E, Showalter TN, Royce TJ, Todorovic T, Huang HC, Houck SA, Yamashita R, Kiess AP, Song DY, Lotan T, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Esteva A, Feng FY, Tran PT, Sutera P, Ost P. Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer. Radiother Oncol. 2025 Jan;202:110618. doi: 10.1016/j.radonc.2024.110618. Epub 2024 Nov 6. PMID: 39510141; PMCID: PMC11663099.
 
297. Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, Tran P, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. Clin Cancer Res. 2025 Mar 17;31(6):1142-1149. doi: 10.1158/1078-0432.CCR-24-3027. PMID: 39820657; PMCID: PMC11911805.
 
298. Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, Tran P, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. Clin Cancer Res. 2025 Mar 17;31(6):1142-1149. doi: 10.1158/1078-0432.CCR-24-3027. PMID: 39820657; PMCID: PMC11911805.
 
299. Guévelou JL, Sargos P, Ost P, Alongi F, Arcangeli S, Berlin A, Blanchard P, Bruynzeel A, Chapet O, Dal Pra A, Dess RT, Guckenberger M, Loblaw A, Kishan AU, Jereczek-Fossa B, Pasquier D, Shelan M, Siva S, Tree AC, Zamboglou C, Supiot S, Murthy V, Zilli T. Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey. Clin Transl Radiat Oncol. 2024 Dec 30;51:100907. doi: 10.1016/j.ctro.2024.100907. PMID: 39845565; PMCID: PMC11751415.
 
300. Lehrer EJ, Khunsriraksakul C, Garrett S, Trifiletti DM, Sheehan JP, Guckenberger M, Louie AV, Siva S, Ost P, Goodman KA, Dawson LA, Tchelebi LT, Yang JT, Showalter TN, Park HS, Spratt DE, Kishan AU, Gupta GP, Shah C, Fanti S, Calais J, Wang M, Schmitz K, Liu D, Abraham JA, Dess RT, Buvat I, Solomon B, Zaorsky NG. Future directions in the evaluation and management of newly diagnosed metastatic cancer. Crit Rev Oncol Hematol. 2025 Apr;208:104631. doi: 10.1016/j.critrevonc.2025.104631. Epub 2025 Jan 24. PMID: 39864534.
 
301. Verghote F, Rammant E, Dirix P, Van Praet C, Berghen C, Junius S, Liefhooghe N, Noé L, Ost P, Decaestecker K, Villeirs G, Decruyenaere A, De Man K, Verbeke S, De Maeseneer D, Fonteyne V. Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial-Results of Secondary Endpoints. Eur Urol Focus. 2025 Jul;11(4):595-602. doi: 10.1016/j.euf.2025.02.005. Epub 2025 Feb 19. PMID: 39971695.
 
302. De Cooman B, Debacker T, Adams T, Lamberts G, De Troyer B, Claessens M, De Kerf G, Mercier C, Dirix P, Ost P. Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis. Radiat Oncol. 2025 Feb 21;20(1):25. doi: 10.1186/s13014-025-02598-8. PMID: 39985052; PMCID: PMC11846345.
 
303. Stas D, De Kerf G, Claessens M, Karlhede A, Söderberg J, Dirix P, Ost P. Incorporating indirect MRI information in a CT-based deep learning model for prostate auto-segmentation. Radiother Oncol. 2025 May;206:110806. doi: 10.1016/j.radonc.2025.110806. Epub 2025 Feb 21. PMID: 39988305.
 
304. Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, Fodor C, Netti S, Zerini D, Luzzago S, Mistretta FA, Venetis K, Cursano G, Burla T, Mazzocco K, Cattani F, Petralia G, Fusco N, Pravettoni G, Musi G, De Cobelli O, Tang C, Ost P, Palma DA, Orecchia R, Jereczek-Fossa BA. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025 Mar;26(3):300-311. doi: 10.1016/S1470-2045(24)00730-7. PMID: 40049196.
 
305. Portik D, Lacombe D, Faivre-Finn C, Achard V, Andratschke N, Correia D, Spalek M, Guckenberger M, Ost P, Ehret F. The 2024 State of Science report from the European Organisation for Research and Treatment of Cancer's Radiation Oncology Scientific Council. Eur J Cancer. 2025 May 2;220:115334. doi: 10.1016/j.ejca.2025.115334. Epub 2025 Mar 3. PMID: 40127505.
 
306. Miszczyk M, Bilski M, Kói T, Konat-Bąska K, Suleja A, Fazekas T, Matsukawa A, Tsuboi I, Schulz R, Rajwa P, Laukhtina E, Hassler MR, Marvaso G, Sargos P, Ost P, Ploussard G, Jereczek-Fossa B, Roupret M, Chłosta P, Karakiewicz PI, Babjuk M, Teoh JY, Moschini M, Gontero P, Shariat SF. Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Focus. 2025 Jul;11(4):638-647. doi: 10.1016/j.euf.2025.03.011. Epub 2025 Apr 2. PMID: 40175243.
 
307. Crippa A, Laere B, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Hjälm-Eriksson M, Pettersson L, Enblad G, Ullén A, Lumen N, Karlsson CT, Sandzén J, Jänes E, Ghysel C, Olsson M, Sautois B, Schatteman P, Roock W, Bruwaene SV, Verbiene I, Darras J, Everaert E, Maeseneer D, Anden M, Strijbos M, Luyten D, Mortezavi A, Oldenburg J, Ost P, Lindberg J, Grönberg H, Eklund M; ProBio Investigators. Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. Eur Urol Oncol. 2025 Dec;8(6):1486-1495. doi: 10.1016/j.euo.2025.02.002. Epub 2025 Apr 21. PMID: 40263079.
 
308. Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Duthoy W, Mach N, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, Zilli T. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025 Jun;26(6):695-706. doi: 10.1016/S1470-2045(25)00197-4. Epub 2025 May 5. PMID: 40339593.
 
309. Mercier C, Billiet C, Ost P, Vandecasteele K, De Kerf G, Claessens M, Van Laere S, Vermeulen P, Dirix L, Lievens Y, Verellen D, Dirix P. Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial. J Clin Oncol. 2025 Jul;43(19):2164-2172. doi: 10.1200/JCO-24-01447. Epub 2025 May 8. PMID: 40340551.
 
310. Achard V, Abdel-Aty H, Duque-Santana V, Bebek M, Kroese TE, Orazem M, Dirix P, Ost P, Lancia A. Combining Radiation Therapy With Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review From the Y-ECI ROSC EORTC Group. Pract Radiat Oncol. 2025 Nov-Dec;15(6):610-624. doi: 10.1016/j.prro.2025.05.004. Epub 2025 May 22. PMID: 40412484.
 
311. Singh M, Murthy V, Ost P. Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer. Semin Radiat Oncol. 2025 Jul;35(3):423-432. doi: 10.1016/j.semradonc.2025.04.012. PMID: 40516977.
 
313. Vandekerkhove G, Murtha AJ, Müller DC, Stephenson M, Rostin K, Munzur AD, Vasquez-Rios C, Nikkola J, Sipola J, Annala M, Herberts C, Fung E, Atwal J, Al-Subaie S, Parekh K, Bernales CQ, Donnellan G, Finch D, Noonan K, Ko JJ, Ozgun G, Nappi L, Kollmannsberger C, Lavoie JM, Parimi S, Todenhöfer T, Ost P, Wang G, Black PC, Maurice-Dror C, Chi KN, Eigl BJ, Wyatt AW. ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer. Clin Cancer Res. 2025 Sep 2;31(17):3725-3741. doi: 10.1158/1078-0432.CCR-24-3912. PMID: 40540011.
 
314. Schröder C, Zwahlen DR, Schär S, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Beck M, Riesterer O, Thalmann GN, Aebersold DM, Ghadjar P; Swiss Group for Clinical Cancer Research SAKK. Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial. Radiother Oncol. 2025 Oct;211:111040. doi: 10.1016/j.radonc.2025.111040. Epub 2025 Jul 8. PMID: 40639766.
 
315. Zamboglou C, Doncker W, Christoforou AT, Arcangeli S, Berlin A, Blanchard P, Bauman G, Campi R, Castro E, Choudhury A, Pra AD, Draulans C, Desai N, Ferentinos K, Francolini G, Gillessen S, Grosu AL, Rivas JG, Hoelscher T, Hruby G, Jereczek-Fossa BA, Kamran S, Kasivisvanathan V, Kishan AU, Kounnis V, Loblaw A, Martin J, Mastroleo F, Merseburger AS, Miszczyk M, Mohamad O, Ost P, Papatsoris A, Peeken JC, Sanguedolce F, Sargos P, Schmidt-Hegemann N, Seibert TM, Shelan M, Siva S, Soeterik TFW, Spratt DE, Stenzl A, Strouthos I, Sutera P, Supiot S, Tilki D, Tran PT, Tree AC, Tward J, Ürün Y, Vapiwala N, Waddle MR, Wegener E, Zilli T, Murthy V, Thieme AH, Spohn S. oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus. Radiother Oncol. 2025 Sep;210:111039. doi: 10.1016/j.radonc.2025.111039. Epub 2025 Jul 9. PMID: 40645505.
 
316. Meattini I, Aznar MC, Boldrini L, Borgmann K, Clark CH, Faivre-Finn C, Forde E, van der Heide UA, Jereczek-Fossa BA, Jornet N, Kirby AM, Ost P, Ratosa I, Tanderup K, Troost EGC, Cortese AJ, Guckenberger M. Repositioning Radiation Oncology at the centre of integrated oncology care: A manifesto of the European Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2025 Sep;210:111035. doi: 10.1016/j.radonc.2025.111035. Epub 2025 Jul 12. PMID: 40659192.
 
317. Weidhaas JB, McGreevy KM, Marco N, Sundahl N, Cabanski CR, Spencer C, LaVallee T, Ost P, Telesca D. Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy. J Transl Med. 2025 Jul 28;23(1):848. doi: 10.1186/s12967-025-06842-3. PMID: 40721801; PMCID: PMC12306077.
 
318. Ost P, Zilli T; STORM collaborators. Reflections on the PEACE V-STORM trial - Authors' reply. Lancet Oncol. 2025 Aug;26(8):e410-e411. doi: 10.1016/S1470-2045(25)00423-1. PMID: 40744040.
 
319. Slevin F, Brown SR, Ost P, Henry AM. The POINTER-PC Study-determining Optimal Radiotherapy for Pelvic Nodal Recurrence in Prostate Cancer. Clin Oncol (R Coll Radiol). 2025 Oct;46:103912. doi: 10.1016/j.clon.2025.103912. Epub 2025 Jul 26. PMID: 40816138.
 
320. Mercier C, Billiet C, Ost P, Vandecasteele K, De Kerf G, Claessens M, Vermeulen P, Dirix L, Lievens Y, Verellen D, Dirix P. Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?". J Clin Oncol. 2025 Nov;43(31):3424-3425. doi: 10.1200/JCO-25-01686. Epub 2025 Sep 8. PMID: 40921011.
 
321. Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J, Eiber M, Fanti S, Fendler WP, Fizazi K, Gafita A, Gillessen S, Goffin K, Hadaschik B, Hofman MS, Hope TA, Maurer T, Morgans AK, Morris MJ, Murphy DG, Oprea-Lager DE, Ost P, ÓSullivan JM, Rouvière O, Sandhu S, Sartor O, Sathekge MM, Tempany C, Witjes W, Emmett L, Bjartell AS. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. 2025 Sep 12:S0302-2838(25)00482-8. doi: 10.1016/j.eururo.2025.08.005. Epub ahead of print. PMID: 40945999.
 
322. Marvaso G, Francolini G, Achard V, Gomez-Iturriaga A, Slevin F, Zilli T, Ost P; Urology Focus Group of the European Society for Radiotherapy and Oncology. Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging. Eur Urol. 2026 Jan;89(1):5-7. doi: 10.1016/j.eururo.2025.08.020. Epub 2025 Sep 13. PMID: 40947367.
 
323. Van den Eynde L, Ost P, Verla W, Everaerts W, Fransis K, Uvin P, Ameye F, Van Erps T, Fonteyne V, Van Praet C, Lumen N. Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer. BJU Int. 2025 Dec;136(6):1121-1127. doi: 10.1111/bju.70006. Epub 2025 Sep 20. PMID: 40974177.
 
324. Sutera P, Van der Eecken K, Song Y, Shetty AC, Davicioni E, Proudfoot JA, Hakansson A, English K, Wang J, Guler OC, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Hathout L, Ennis R, Jabbour SK, Saraiya B, Stephenson R, Mayer T, Mishra M, Rana Z, Molitoris J, Kiess A, Song DY, DeWeese T, Pienta KJ, Tran PT, Berlin A, Onal C, Ost P, Deek MP. Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy. Eur Urol Oncol. 2025 Sep 20:S2588-9311(25)00199-3. doi: 10.1016/j.euo.2025.07.007. Epub ahead of print. PMID: 40976747.
 
325. Kleiburg F, Dirix P, Fonteyne V, Bral S, De Troyer B, Sautois B, Lamande M, Liefhooghe N, Grisay G, Meersschout S, Vandermeulen A, Jullian N, Staelens L, Poelaert F, Strijbos M, Verschueren J, Goffin K, Withofs N, Ost P. Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial. Eur Urol Oncol. 2025 Oct;8(5):1333-1339. doi: 10.1016/j.euo.2025.08.005. Epub 2025 Sep 25. PMID: 40998687.
 
326. Van Hemelrijck M, Ost P, Gandaglia G. Editorial: The need for pragmatic trials in genitourinary oncology. Front Oncol. 2025 Oct 2;15:1702188. doi: 10.3389/fonc.2025.1702188. PMID: 41114351; PMCID: PMC12529112.
 
327. Francolini G, Ost P, Zilli T. Re: Carlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al. Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.019. Eur Urol Focus. 2025 Nov 7:S2405-4569(25)00294-9. doi: 10.1016/j.euf.2025.10.008. Epub ahead of print. PMID: 41206242.
 
328. Walz J, Attard G, Bjartell A, Blanchard P, Castro E, Compérat E, Emmett L, Fanti S, Fonteyne V, Foulon S, Gillessen S, Gravis G, James ND, Oprea-Lager DE, Ost P, Padhani A, Parker C, Renard-Penna RM, Rubin MA, Saad F, Sweeney C, Tilki D, Tombal B, Tree AC, Zilli T, Fizazi K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Dec 18:S0923-7534(25)06330-6. doi: 10.1016/j.annonc.2025.12.009. Epub ahead of print. PMID: 41421764.
 
329. Van den Eynde L, Ost P, Lumen N. Authors' reply to: comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'. BJU Int. 2025 Nov 27. doi: 10.1111/bju.70098. Epub ahead of print. PMID: 41309109.
 
330. Le Guevelou J, Zilli T, Ferrario F, Murthy V, Tree A, Loblaw A, Van der Heide UA, Kishan A, Draulans C, Martin J, Ost P, Sargos P. Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. Prostate Cancer Prostatic Dis. 2025 Dec 23. doi: 10.1038/s41391-025-01071-7. Epub ahead of print. PMID: 41437135.
 
331. Kaidar-Person O, Sklair-Levy M, Anaby D, Bernstein-Molho R, van Maaren MC, de Munck L, de Ruysscher D, Offersen B, Poortmans P, Boersma LJ; SECRET group. Residual breast tissue after mastectomy and reconstruction: A substudy of the Spatial location of breast cancer local rECurRence aftEr masTectomy (SECRET) project. Eur J Surg Oncol. 2024 Nov;50(11):108607. doi: 10.1016/j.ejso.2024.108607. Epub 2024 Aug 16. PMID: 39191132.
 
332. Lee SF, Kennedy SKF, Caini S, Wong HCY, Yip PL, Poortmans PM, Meattini I, Kaidar-Person O, Recht A, Hijal T, Torres MA, Cao JQ, Corbin KS, Choi JI, Koh WY, Kwan JYY, Karam I, Chan AW, Chow E, Marta GN. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis. BMJ. 2024 Sep 11;386:e079089. doi: 10.1136/bmj-2023-079089. PMID: 39260879; PMCID: PMC11388113.
 
333. Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, Hindié E, Pilkington Woll JP, Jacene H, Rubio IT, Vrancken Peeters MJ, Dibble EH, de Geus-Oei LF, Graff SL, Cardoso F. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. Breast. 2024 Dec;78:103806. doi: 10.1016/j.breast.2024.103806. Epub 2024 Sep 12. PMID: 39303572; PMCID: PMC11440802.
 
334. Kaidar-Person O, Boersma LJ, De Brouwer P, Weltens C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Peters M, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Bartelink H, Struikmans H, Fortpied C, Poortmans PM; EORTC Radiation Oncology and Breast Cancer Groups. The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies. Radiother Oncol. 2024 Dec;201:110563. doi: 10.1016/j.radonc.2024.110563. Epub 2024 Sep 26. PMID: 39341505.
 
335. Colciago RR, Lancellotta V, De Santis MC, Bonzano E, De Rose F, Rocca E, Meduri B, Pasinetti N, Prisco A, Gennari A, Tramm T, Di Cosimo S, Harbeck N, Curigliano G, Poortmans P, Meattini I, Franco P. The role of radiation therapy in the multidisciplinary management of male breast cancer: A systematic review and meta-analysis on behalf of the Clinical Oncology Breast Cancer Group (COBCG). Crit Rev Oncol Hematol. 2024 Dec;204:104537. doi: 10.1016/j.critrevonc.2024.104537. Epub 2024 Oct 23. PMID: 39454738.
 
336. Kaidar-Person O, Strnad V, Ratosa I, Boersma L, Poortmans P. In Regard to Shaitelman et al. Pract Radiat Oncol. 2024 Nov-Dec;14(6):608-612. doi: 10.1016/j.prro.2023.12.015. PMID: 39487012.
 
337. Sessa C, Travado L, Calaminus G, Cunha TM, Delgado Bolton RC, van Driel W, Fernandes A, Hutka M, Lemley B, Luczak N, Medeiros R, Oberst S, Ottevanger N, Papadia A, Pereira P, Rodrigues M, Stolnicu S, Vandecasteele K, Costa A, Poortmans P, Peccatori F. European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team. Tumori. 2025 Feb;111(1):11-19. doi: 10.1177/03008916241303022. Epub 2024 Dec 6. PMID: 39643948.
 
338. Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L; EUROPA Trial Investigators. Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial. Lancet Oncol. 2025 Jan;26(1):37-50. doi: 10.1016/S1470-2045(24)00661-2. Epub 2024 Dec 12. PMID: 39675376.
 
339. Gasparri ML, Kaidar-Person O, Gentilini OD, de Boniface J, Kuehn T, Poortmans P. Radiation therapy volumes after primary systemic therapy in breast cancer patients: an international EUBREAST survey. Radiat Oncol J. 2024 Dec;42(4):308-318. doi: 10.3857/roj.2024.00248. Epub 2024 Dec 16. PMID: 39748531; PMCID: PMC11701460.
 
340. Meattini I, Coles CE, Tramm T, Borghesi S, Krug D, Montero A, Nardone V, Salvestrini V, Valzano M, Valentini V, Aristei C, Poortmans P; Assisi Think Tank Meeting Investigators. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol. 2025 Mar 1;11(3):329-339. doi: 10.1001/jamaoncol.2024.5780. PMID: 39820307.
 
341. Arenas M, Bölükbaşı Y, Boersma LJ, Offersen B, Kouloulias V, Palumbo I, Trigo L, Lozza L, Marazzi F, Trovo M, Rivera S, Kaidar-Person O, Coles C, Meattini I, Valentini V, Aristei C, Poortmans P; Assisi Think Tank Meeting (ATTM) 2024 members. The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy. Breast. 2025 Apr;80:103881. doi: 10.1016/j.breast.2025.103881. Epub 2025 Jan 20. PMID: 39854807; PMCID: PMC11804728.
 
342. Moshe N, Haisraely O, Globus O, Faermann R, Abu-Shehada N, Anaby D, Gal Yam E, Balint Lahat N, Galper S, Menes T, Haik J, Sklair-Levy M, Oedegaard C, Kuehn T, Morrow M, Poortmans P, Bernstein-Molho R, Kaidar-Person O. Breast cancer outcomes after skin- and nipple-sparing mastectomy in BRCA pathogenic mutation carriers versus non-BRCA carriers. Radiother Oncol. 2025 Apr;205:110710. doi: 10.1016/j.radonc.2025.110710. Epub 2025 Jan 23. PMID: 39862923.
 
343. Bernstein-Molho R, Haisraely O, Galper S, Abu-Shhada N, Nili Gal-Yam E, Menes TS, Poortmans P, Kaidar-Person O. The impact of loco-regional treatment on ipsilateral breast cancer recurrence and outcomes in carriers of BRCA1/2 pathogenic variants. Breast Cancer Res Treat. 2025 Jun;211(2):431-439. doi: 10.1007/s10549-025-07658-x. Epub 2025 Mar 5. PMID: 40042736; PMCID: PMC12006241.
 
344. Dzhugashvili M, Serradilla A, Fernández-Ibiza J, García G, Malinochka KM, Torres L, Seral A, Begara J, Gonsalves D, Troca JJC, Poortmans P, Couñago F, López E. Ultrahypofractionation and Simultaneous Integrated Boost in Breast Cancer: Early Side Effects Analysis. Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):241-248. doi: 10.1016/j.ijrobp.2025.02.003. Epub 2025 Mar 11. PMID: 40072398.
 
345. Salagean GA, Bálint Z, Poortmans P, Portik D. Can the daily position of bolus material influence radiotherapy treatment? Rep Pract Oncol Radiother. 2025 Feb 19;29(6):732-739. doi: 10.5603/rpor.104013. PMID: 40104657; PMCID: PMC11912895.
 
346. Groheux D, Vaz SC, de Geus-Oei LF, Dibble EH, Ulaner GA, Cook GJR, Hindié E, Poortmans P, Mann RM, Jacene H, Pilkington Woll JP, Rubio IT, Vrancken Peeters MJ, Graff SL, Cardoso F. [18F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer. J Clin Oncol. 2025 Jun 10;43(17):1942-1947. doi: 10.1200/JCO-24-01945. Epub 2025 Mar 25. PMID: 40132148.
 
347. Meattini I, Livi L, Poortmans PMP; EUROPA Trial Steering Committee. EUROPA trial: cost implications of radiotherapy versus endocrine therapy - Authors' reply. Lancet Oncol. 2025 Apr;26(4):e183. doi: 10.1016/S1470-2045(25)00090-7. PMID: 40179910.
 
348. Ho F, Swart R, Boersma L, Fijten R, Cremers P, van Merode F, Jacobs M; Collaborative expert group implementation protocol for radiotherapy innovations. The road to successful implementation of innovation in radiotherapy: A research-based implementation protocol. Radiother Oncol. 2025 Jun;207:110874. doi: 10.1016/j.radonc.2025.110874. Epub 2025 Apr 3. PMID: 40187498.
 
349. Wintraecken VM, van Roozendaal LM, Simons JM, de Vries J, van Kuijk SMJ, Vane MLG, van Dalen T, Sackey H, van der Hage JA, Strobbe LJA, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, van de Vijver KKBT, Westenberg HH, Dirksen CD, de Wilt JHW, Boersma LJ, Smidt ML. Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: Impact of personality traits on health-related quality of life. Br J Surg. 2025 Apr 30;112(5):znaf031. doi: 10.1093/bjs/znaf031. PMID: 40365927; PMCID: PMC12076147.
 
350. Beddok A, Willmann J, Embring A, Appelt AL, Balermpas P, Chua K, Choi JI, Elger BS, Gabrys D, Hoskin P, Niyazi M, Pasquier D, Paradis K, Kaidar-Person O, Plaisier C, Schmitt NC, Steuer CE, Thariat J, Yom SS, Poortmans P, Vasquez Osorio E, Andratschke N. Reirradiation: Standards, challenges, and patient-focused strategies across tumor types. CA Cancer J Clin. 2025 Nov-Dec;75(6):630-666. doi: 10.3322/caac.70016. Epub 2025 May 29. PMID: 40438993; PMCID: PMC12593330.
 
351. Kaidar-Person O, Poortmans P, Meattini I, Tramm T. An additional peril of pathologic complete response. Radiother Oncol. 2025 Aug;209:110962. doi: 10.1016/j.radonc.2025.110962. Epub 2025 May 27. PMID: 40441489.
 
352. Kaidar-Person O, Poortmans P, Offersen BV, Meattini I, Tramm T, Steyerova P, Dodwell D, de Boniface J, Boersma LJ. Optimising mastectomy with a focus on skin and nipple-sparing approaches: a multidisciplinary point of view. Eur J Surg Oncol. 2025 Oct;51(10):110310. doi: 10.1016/j.ejso.2025.110310. Epub 2025 Jul 4. PMID: 40683072.
 
353. Amant F, Planchamp F, Berveiller P, Cardonick E, De Middelaer A, Fruscio R, Fumagalli M, Johansson ALV, Lambertini M, LeJeune CL, Lok C, McCluggage WG, Poortmans P, Sienko J, Hjortshøj CS, Swierczynska M, Testa AC, Van Assche IA, Van Calsteren K, Vandecaveye V, Versteeg C, Zagouri F, Zapardiel I, Halaska MJ. ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy. Int J Gynecol Cancer. 2025 Sep;35(9):101975. doi: 10.1016/j.ijgc.2025.101975. Epub 2025 Jun 13. PMID: 40707270.
 
354. Kaidar-Person O, Pfob A, Valentini V, Aznar M, Dekker A, Meattini I, de Boniface J, Krug D, Cardoso MJ, Curigliano G, Dubsky P, Poortmans P. Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study. Breast. 2025 Oct;83:104537. doi: 10.1016/j.breast.2025.104537. Epub 2025 Jul 15. Erratum in: Breast. 2025 Oct;83:104557. doi: 10.1016/j.breast.2025.104557. PMID: 40763489; PMCID: PMC12341621.
 
355. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy. Lancet. 2025 Aug 9;406(10503):603-614. doi: 10.1016/S0140-6736(25)01013-X. Erratum in: Lancet. 2025 Sep 27;406(10510):1340. doi: 10.1016/S0140-6736(25)01638-1. PMID: 40783288.
 
356. Kaidar-Person O, Pfob A, Valentini V, Aznar M, Dekker A, Meattini I, de Boniface J, Krug D, Cardoso MJ, Curigliano G, Dubsky P, Poortmans P. Corrigendum to "Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study" [The Breast, Volume 83 (2025) 104537]. Breast. 2025 Oct;83:104557. doi: 10.1016/j.breast.2025.104557. Epub 2025 Aug 19. Erratum for: Breast. 2025 Oct;83:104537. doi: 10.1016/j.breast.2025.104537. PMID: 40834677; PMCID: PMC12395143.
 
357. Kaidar-Person O, Poortmans P. A Partial Remission Is a Complete Failure: Benefits of Locoregional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025 Nov 1;123(3):613-614. doi: 10.1016/j.ijrobp.2025.05.007. PMID: 40998480.
 
358. Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP; Panelists of the St. Gallen International Breast Cancer Consensus 2025. Electronic address: https://twitter.com/SG_BCC; Panelists of the St. Gallen International Breast Cancer Consensus 2025. Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Ann Oncol. 2025 Dec;36(12):1433-1446. doi: 10.1016/j.annonc.2025.09.007. Epub 2025 Oct 8. PMID: 41072918.
 
359. Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Federmann J, Finestone S, Gnant M, Hlauschek D, Iwata H, Jiang MY, Kaidar-Person O, Lee HB, MacKenzie M, Meyn A, Poortmans P, Poulakaki F, Richardson AL, Sepulveda KA, Spillane AJ, Thompson AM, Werutsky G, Wittmann P, Wright JL, Zdenkowski N, Cowan K, McIntosh SA; PRECEDENT Study Group. A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials. NPJ Breast Cancer. 2025 Oct 28;11(1):116. doi: 10.1038/s41523-025-00824-w. PMID: 41152314; PMCID: PMC12568921.
 
360. Zamagni A, Montero Luis A, Mjaaland I, Chirila ME, Ciervide R, Machiels M, Ratosa I, Van Den Bongard DHJG, Aznar M, Boersma LJ, Coles CE, Corradini S, Caluwe A, Gabrys D, Kaidar-Person O, Kirby AM, Krug D, Maraldo MV, Meattini I, Rivera S, Somaiah N, Strnad V, Zeidan Y, Poortmans P. ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives - Endorsed by ASTRO. Radiother Oncol. 2026 Jan;214:111236. doi: 10.1016/j.radonc.2025.111236. Epub 2025 Oct 27. PMID: 41161390.
 
361. Hannoun-Levi JM, Margenthaler J, Anderson B, Di Micco R, Arthur D, Aznar M, Berry MP, Brown T, Burke E, de Boniface J, Dietz J, Dodwell D, Fredriksson I, Gentilini OD, Guix B, Gutierrez C, Haidinger R, Heditsian D, Kothari A, LeStage B, Lyons J, McLean YF, MacKenzie M, Meattini I, Montero-Luis A, Mourtada F, Nguyen T, Petitti L, Polgar C, Poortmans P, Rocco N, Sackey H, Sarantou T, Showalter S, Strnad V, Kuehn T, Volders J, Vrancken Peeters MJ, Yashar C, Rubio IT, Gahm J, Zeidan Y, Kaidar-Person O, Dirbas FM. Local management of second breast cancer event after primary breast conserving therapy: The patient's perspective. Eur J Surg Oncol. 2025 Dec;51(12):110484. doi: 10.1016/j.ejso.2025.110484. Epub 2025 Sep 27. PMID: 41176889.
 
362. Pfob A, Pinker K, Vaz-Luis I, Di Meglio A, Cardoso MJ, Curigliano G, Gentilini OD, Gruber G, Hauser N, Heil J, Kaidar-Person O, Knauer M, Lee HB, Lee SB, Loi S, Mannhart M, Mastora S, Meattini I, Di Micco R, Noske A, Peccatori FA, Poulakaki F, Reinisch M, Rubio IT, Swanton C, Tausch C, Vrancken Peeters MJ, Yu JH, Weber WP, Zerbe N, Poortmans P, Denkert C, Mann R, Delaloge S, Dubsky P; Toolbox 3 Consortium. The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus. Lancet Oncol. 2025 Dec;26(12):e694-e706. doi: 10.1016/S1470-2045(25)00463-2. PMID: 41308690.
 
363. Marta GN, Kaidar-Person O, Meattini I, Poortmans P. De-escalating locoregional radiation therapy in breast cancer: balancing promises and prudence. Expert Rev Anticancer Ther. 2025 Dec 19:1-8. doi: 10.1080/14737140.2025.2604616. Epub ahead of print. PMID: 41390975.
 
364. Alaverdashvili T, Montero A, Poortmans P. Global perspective on implementing ultra-hypofractionated radiation therapy in breast cancer: a survey-based analysis. Clin Transl Oncol. 2025 Dec 19. doi: 10.1007/s12094-025-04156-w. Epub ahead of print. PMID: 41417445.
 
365. Rammant E, Deman E, Fonteyne V, Poppe L, Bultijnck R, Dirix P, De Meerleer G, Haustermans K, Van Hecke A, Aguado-Barrera ME, Avuzzi B, Azria D, Chang-Claude J, Chiorda BN, Choudhury A, Calvo-Crespo P, De Ruysscher D, Gómez-Caamaño A, Heumann P, Hopkins AM, Johnson K, Lambrecht M, Mcwilliam A, Menz BD, Poelaert F, Rancati T, Rans K, Rattay T, Rosenstein BS, Seibold P, Shortall J, Sperk E, Sundahl N, Talbot CJ, Vega A, Vermeulen P, Webb A, West CML, Veldeman L, Van Hoecke S; REQUITE consortium. Using machine learning to predict patient-reported symptom clusters in prostate cancer patients receiving radiotherapy. Health Qual Life Outcomes. 2025 Nov 29. doi: 10.1186/s12955-025-02460-1. Epub ahead of print. PMID: 41318568.
 
366. Mair MJ, Lohmann P, Galldiks N, Belting M, Brandal P, Broen MPG, Cicone F, Daisne JF, Ducray F, Ehret F, Furtner J, Jakola AS, Niyazi M, Pellerino A, Rasschaert M, Razis E, Sahm F, Smits M, Tolboom N, Verger A, Le Rhun E, Minniti G, Weller M, Preusser M, Albert NL. Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey. Eur J Nucl Med Mol Imaging. 2025 Oct;52(12):4627-4638. doi: 10.1007/s00259-025-07366-0. Epub 2025 Jun 4. PMID: 40464806; PMCID: PMC12491378.
 
367. Juul SJ, Rossetti S, Aleman BMP, van Leeuwen FE, van der Kaaij MAE, Giusti F, Meijnders P, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Krzisch D, Bigenwald C, Stamatoullas A, André M, Plattel WJ, Hutchings M, Maraldo MV. Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials. J Cancer Surviv. 2024 Oct 18. doi: 10.1007/s11764-024-01694-0. Epub ahead of print. PMID: 39422824.
 
368. Elsayad K, Guenova E, Assaf C, Nicolay JP, Trautinger F, Stadler R, Waldstein C, Boterberg T, Meijnders P, Kirova Y, Dobos G, Duque-Santana V, Riggenbach E, Elsheshtawy W, Niezink A, Papadavid E, Scarisbrick J, Vermeer M, Neelis KJ, Bagot M, Battistella M, Quaglino P, Knobler R, Kempf W, Maklad A, Adeberg S, Kouloulias V, Simontacchi G, Corradini S, König L, Eich HT, Cowan R, Correia D. Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group. Eur J Cancer. 2024 Nov;212:115064. doi: 10.1016/j.ejca.2024.115064. Epub 2024 Oct 8. PMID: 39418694.
 
369. Stas D, Vandamme T, Roeyen G, Reynders D, Demey W, Stellamans K, Bussels B, Hutsebaut I, Maurissen I, Bouchart C, Berbée M, Lallemand F, Poels H, Thomas M, Cuyle PJ, Bulens P, Verboven K, Martens M, Weytjens R, Joye I. Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). BMC Cancer. 2025 Oct 30;25(1):1671. doi: 10.1186/s12885-025-15041-8. PMID: 41168707; PMCID: PMC12574135.
 
370. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Palme JÖ, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Traa T, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Änghede Haraldsson A, Billiet C, Lewensohn R, Lindberg K. Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS study. Lung Cancer. 2025 May;203:108527. doi: 10.1016/j.lungcan.2025.108527. Epub 2025 Mar 31. PMID: 40184836.
 
371. Guckenberger M, Wilke L, Billiet C, Rogers S, Franzese C, Schnell D, Spałek M, Aebersold DM, Hemmatazad H, Zilli T, Boda-Heggemann J, Baumert BG, Stelmes JJ, Nägler F, Gut P, Weiß C, Bruni A, Zimmermann F, Förster R, Zimmer J, Madani I. Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial. Radiother Oncol. 2025 Jul;208:110940. doi: 10.1016/j.radonc.2025.110940. Epub 2025 May 14. PMID: 40378895.
 
372. Halilaj I, Lieverse R, Oberije C, Hendriks L, Billiet C, Joye I, Van Eeckhout B, Wind A, Ankolekar A, Lambin P. Improving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study. J Med Internet Res. 2025 Sep 10;27:e71817. doi: 10.2196/71817. PMID: 40931488; PMCID: PMC12422530.
 
373. van Loosbroek SY, Milder MTW, de Ruysscher D, Vaes RDW, den Toom W, Willemssen F, Eskens F, Homs MYV, Groot Koerkamp B, van Driel LMJW, Seppenwoolde Y, van Werkhoven E, Intven M, Haj Mohammad N, de Bruijne J, Versteijne E, Bruynzeel AM, Brandts F, Erdmann JI, Westdorp H, Braam PM, Tjwa ETTL, Bouchart C, Demols A, Gulyban A, Buijsen J, de Vos-Geelen J, Dewulf M, Joye I, Vandamme T, Vonghia L, de Groot DJ, Dieters M, Ubbels FJF, Hoogwater FJH, Heijmen B, Méndez Romero A PHD. STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study. BMJ Open. 2025 Jul 16;15(7):e097545. doi: 10.1136/bmjopen-2024-097545. PMID: 40669914; PMCID: PMC12273127.
 
374. Klein J, Tran WT, Viswanathan S, Salgado R, Poortmans P, Machiels M. Tumour-infiltrating Lymphocytes and Radiation Therapy in Rectal Cancer: Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol). 2025 Mar;39:103742. doi: 10.1016/j.clon.2024.103742. Epub 2024 Dec 20. PMID: 39854781.
 
375. Esposito M, Baldoni R, Bossuyt E, Bresciani S, Clark CH, Jones M, Kry S, Perry J, van de Kamer J, Verellen D, Jornet N. A commissioning protocol for portal imaging-based radiotherapy in vivo dosimetry systems. Phys Imaging Radiat Oncol. 2024 Nov 1;32:100666. doi: 10.1016/j.phro.2024.100666. PMID: 39624392; PMCID: PMC11609462.
 
376. Kuncman Ł, la Pinta C, Milder MTW, Romero AM, Guckenberger M, Franzese C, Scorsetti M, Bruc B, Verellen D, Tanadini-Lang S. Definition and requirements for stereotactic radiotherapy: a systematic review. Radiother Oncol. 2025 Oct;211:111107. doi: 10.1016/j.radonc.2025.111107. Epub 2025 Aug 15. PMID: 40819673.
 
377. De Kerf G, Barragán-Montero A, Brouwer CL, Pisciotta P, Biston MC, Fusella M, Herbin G, Kneepkens E, Marrazzo L, Mason J, Nielsen CP, Snijders K, Tanadini-Lang S, Vaandering A, Janssen TM. Multicentre prospective risk analysis of a fully automated radiotherapy workflow. Phys Imaging Radiat Oncol. 2025 Apr 6;34:100765. doi: 10.1016/j.phro.2025.100765. PMID: 40248770; PMCID: PMC12005333.
 
378. Sundström J, Finnson A, Hynning E, De Kerf G, Fredriksson A. Partitioning of multiple brain metastases improves dose gradients in single-isocenter radiosurgery. Med Phys. 2025 Oct;52(10):e18117. doi: 10.1002/mp.18117. PMID: 40973656.
 
379. Dries W, Petoukhova A, Hertsens N, Stevens P, Jarbinet V, Bimmel-Nagel CH, Weterings J, van Wingerden K, Bauwens C, Vanreusel V, Simon S. Intraoperative electron beam intercomparison of 6 sites using mailed thermoluminescence dosimetry: Absolute dose and energy. Phys Med. 2024 Mar;119:103302. doi: 10.1016/j.ejmp.2024.103302. Epub 2024 Feb 3. PMID: 38310679.
 
380. Tobias Böhlen T, Psoroulas S, Aylward JD, Beddar S, Douralis A, Delpon G, Garibaldi C, Gasparini A, Schüler E, Stephan F, Moeckli R, Subiel A. Recording and reporting of ultra-high dose rate "FLASH" delivery for preclinical and clinical settings. Radiother Oncol. 2024 Nov;200:110507. doi: 10.1016/j.radonc.2024.110507. Epub 2024 Sep 6. PMID: 39245070.

  

Deel deze pagina met je netwerk

webversie:

Iridium

Iridium is een netwerk van hooggespecialiseerde radiotherapie met zorg op maat.

SNEL NAAR

Dankzij jouw steun kunnen we inzetten op wetenschappelijk onderzoek binnen de radiotherapie

Iridium Netwerk vzw • Oosterveldlaan 22 • 2610 Antwerpen • BE 0885.546.553 RPR Antwerpen • +32 3 443 37 37 • secretariaat@iridiumnetwerk.be • www.iridiumnetwerk.be
AZ Klina • AZ Monica • AZ Rivierenland • AZ Voorkempen •  UZA • Vitaz • ZAS